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ABSTRACT
Nitric oxide (NO) is a vital gasotransmitter, involved in a plethora of signaling
pathways. With bioavailable NO stored as S-nitrosoglutathione (GSNO), its enzymatic
degradation by S-nitrosoglutathione reductase (GSNOR) has a large impact on cellular
SNO levels. This thesis consists of two components: chapter one explores the production
of NO generating particles, that use chitosan as a matrix for a copper catalyst. Chapter two
reports the discovery into a new regulatory domain on the GSNOR enzyme.
In chapter one, we have developed a novel technology capable of generating NO,
in the form of NO-releasing copper-chitosan particles (Cu-chito). These particles were
successfully tested in their release of authentic NO: the maximum rate of production was
1.40 nmol/min/g. The Cu-chito particle treatments were analysed using scratch assays. In
comparison to control groups: Cu-chito particles, which provide bioactive NO, displayed
130% of cells in the wound, while treatments with supplemented glucose displayed 152%.
This supports the hypothesis that glucose aids to regenerate active copper in the catalytic
cycle of NO production. Matrix metalloproteinases (MMP-2 and -9) were chosen as an
intracellular NO target. The activity MMP was investigated: displayed an increase of 60%
after Cu-chito treatments. The NO treatments provide a lasting effect on a cellular level.
Presented in chapter two is the discovery of a new regulatory domain on GSNOR:
an allosteric binding domain. A sigmoidal deviation in GSNOR kinetics indicated positive
cooperativity for GSNO binding. Molecular docking (MD) simulations indicates the
location a putative allosteric site at the amino acid residues Gly321, Lys323, Asn185, and
Lys188. To further these studies hydrogen / deuterium exchange (HDX) mass spectrometry
(MS) experiments were performed. With a two second HDX reaction, the residues Gly321,
Lys323, and Lys188 displayed a decrease in deuterium uptake of 1.4%, 1.4%, and 0.4%,
after the incorporation of GSNO. These results strongly support the existence of a
secondary binding domain of substrate GSNO that contributes to its mechanism of action.
iv
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CHAPTER 1: Nitric Oxide Generating Copper-Chitosan
Particles

1

1.1 Chapter Summary
Nitric oxide (NO) is a signaling molecule that plays many roles during infection,
inflammation, and wound healing processes. Due to NO’s role in wound repair, we have
developed a novel NO generation system based on copper-chitosan complexes that can be
used for the topical generation of NO. Chitosan, a biocompatible polymer, chelates copper
ions. Copper in the +1 state can reduce nitrite (NO2–) and convert it into NO. With glucose,
a reducing sugar, present in the system, Cu+2 can be returned to Cu+1 to complete the
catalytic cycle. Copper-chitosan milli- and micro- sized particles were produced using
microfluidic techniques. Copper-chitosan milli-particles (Cu-chito) did produce nitric
oxide (NO). The maximum rates of NO production were ~ 1.40 nmol/min/g (Cu-chito) and
1.08 nmol/min/g (Cu-chito + glucose). The milli-particles were tested with ARPE-19 cell
lines in scratch assays, to mimic an in vitro model for wound healing. Cu-chito particle
treatments with nitrite showed 130% new cells in the wound in comparison to chitosan
milli-particles not containing copper. Furthermore, Cu-chito treatments of nitrite + glucose
showed 152% new cells in the wound in comparison to control groups, and 118% in
comparison to Cu-chito with nitrite alone. The activity of intracellular NO target, matrix
metalloproteinases (MMP-2 and -9), were shown to increase by 60% after 48 hours of Cuchito ± glucose treatments.

2

1.2 Introduction
This chapter focuses on the development of a nitric oxide (NO) releasing
technology for the desired application relating to wound healing and other similar medical
or biological fields. In order to do this, the physiological relevance and implications of NO
and other components of the technology must first be described.
1.2.1 Gasotransmitters
Gasotransmitters is a term used to describe a group of small gaseous signaling
molecules consisting of nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide
(H2S). As a group, gasotransmitters have several interesting properties. They are
endogenously produced molecules that have significant roles as physiologic mediators in
the cardiovascular (NO, CO, H2S), immune (NO, CO), and nervous systems (NO, H2S),
while also existing as toxic gasses.1-3 They have high lipid solubilities, can freely pass
through cellular membranes and have specific targets; including the metal centers of
metalloproteins, such as guanylyl cyclase.1-2 For example, the main targets of NO, and
other reactive nitrogen species (RNS), include metal centers and thiols.3
The ability to penetrate the cellular membrane is just one property that distinguishes
gasotransmitters from other, more classical signaling molecules, which could require other
mechanisms, such as binding to plasma membrane receptors in order to reach their targets.12

Since gaseous molecules are not easily stored (i.e. in vesicles), they are produced as

required and diffused out. In turn, the robust reactivity of NO and H2S relates to the
requirement of being subjected to regulatory systems. For example, both molecules will
3

readily react with the cysteine thiol of glutathione, which could yield problematic results
if that is not the intended destination.2 The robust action of NO and H2S is countered by
the body’s ability to biochemically detox them; they are readily metabolized by
cytochrome oxidases (a group of metalloproteins).3-4 In the instance of NO, regulation is
performed by the control of nitic oxide synthases (NOS), the group of enzymes responsible
for its biosynthesis. NO can reach its target by the binding of NOS to the protein target, or
with the aid of scaffolding proteins.2
As it stands, the reaction of NO and H2S with glutathione does a sufficient job of
visualizing the effects that are typical of gasotransmitters; by chemically modifying
intracellular proteins. In contrast to classical messenger molecules mode of action being
amplifying signaling cascades. The chemical reactions of glutathione (GSH) reacting with
NO and H2S are shown in Figure 1.2.1a.

4

Figure 1.2.1a: Glutathione (GSH) reacting with the gasotransmitters NO and H 2S.
Producing S-nitrosoglutathione (GSNO) and oxidized glutathione (GSSH), respectively.

5

1.2.2 Nitric Oxide, the First Gasotransmitter
Nitric oxide (NO), the gaseous radical shown in Figure 1.2.2a, was the first
identified gasotransmitter. The molecule itself was discovered in 1772 by Joseph Priestley.
In the late 1980’s there were breakthroughs in regards to its biological role. The research
group led by Dr. Louis J. Ignarro discovered that NO was the endothelium-derived relaxing
factor (EDRF). This led to him being awarded the Nobel Prize in Medicine in 1998, in
conjunction with Robert F. Furchgott and Ferid Murad for their work with NO. Research
interests took off after NO was named “Molecule of the Year” in 1992.

Figure 1.2.2a: Nitric oxide Lewis dot diagram
NO is produced in the body principally through nitric oxide synthases (NOSs).5-6
In general, NOSs are responsible for the NO produced in eukaryotic cells; they are found
in animals, partly conserved in bacteria and in some algae.7 Other organisms, including
land plants, use alternative methods like nitrite reduction.7
Basal levels of NO are produced by the constitutive isoforms (cNOS) of nitric oxide
synthase, which continuously produces NO in the picomolar to nanomolar levels necessary
for signaling. There are two isoforms of cNOS, one originally discovered in vascular
endothelial cells (eNOS) and a neuronal isoform found in the brain (nNOS), they have
since been discovered in other tissues.8-9 Its role as the EDRF, responsible for the dilation
of blood vessels, is one of its basal functions in vascular endothelial cells. NO activates
soluble guanylate cyclase (sGC), an enzyme involved in vasodilation.10 In the central
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nervous system, NO mediates the increase of cyclic guanosine monophosphate (cGMP)
via the activation of glutamate receptors.11-13 The activation of cGMP controls vascular
tone, participates in the control of blood pressure, and regulates the distribution of flow
between vascular beds, including the brain and skeletal muscles.10
Beyond cNOS, NO can also be produced in larger quantities (micromolar) by the
inducible isoforms of nitric oxide synthase (iNOS), in response to stimuli such as
endotoxins and cytokines, which are often released in response to infections, inflammation,
and other pathologies.10,

14-15

iNOS is calcium-independent and was discovered in

macrophages, with roles in the immune system; with responses to burn injuries, arthritis,
and inflammatory bowel diseases (IBSs).15 At the micromolar levels produced by iNOS,
NO can display toxic effects that work to aid the immune system by killing
microorganisms, viruses, and parasites.10
1.2.3 Downstream NO Signaling & Matrix Metalloproteinase’s (MMP).
NO plays several roles in wound healing. It has a central role in physiological and
pathological processes of angiogenesis where it can promote collagen deposition at the
wound site, which helps to increase the strength of the healed wound.16-18 Inhibition of NO
at a wound site results in a decrease of collagen produced and decreased formation of
granulation tissue.19 In the vasculature, NO can stimulate cell proliferation, provide
protection from apoptosis, prevent against thrombosis, and is the mediator for the vascular
endothelial growth factor (VEGF).17 In addition, NO has been shown to display some
antiplatelet, antiatherosclerotic, haemodynamic and neuroprotective properties.10
Topically applied NO has been shown to increase dermal microcirculation in skin models.20
7

Downstream signaling effects of NO are observed throughout cell physiology. For
example, NO activates guanylyl cyclase which can then produce cyclic guanosine
monophosphate (cGMP). One of cGMP’s signaling roles include the dilation of blood
vessels. Other effects of NO include the influence of other proteins, such as matrix
metalloproteinase’s (MMP). MMP’s play a central proteolytic role in extracellular matrix
remodeling, during processes such as cell proliferation, angiogenesis and more.21 A NO
regulatory effect on the activity of MMPs has been observed. In a wound model by Ridnour
et al. media exhibiting peak MMP activity increased corresponded to a vascular cell
migration that was MMP-9-dependent, which suggested that MMP-9 is a key physiologic
mediator of the effects of NO.22 Multiple pathways of MMP activation by NO have been
discovered: MMP’s are influenced by cGMP (a reaction product of NO), VEGF-stimulated
cerebral MMP has been found to be mediated through NO produced by iNOS, elevated
levels of NO has been found to correspond with MMP activity in diseases like rheumatoid
arthritis, where cartilage breakdown is predominant, or cancer, where rapid remodeling and
angiogenesis takes place.22-24
1.2.4 Medical Effects of NO
Certain disease states and health complications can deteriorate by the body’s
inefficient production of NO, or its decrease in sensitivity to NO. NO activity can be
tracked by the levels of the post translational modification S-nitrosylation (SNO), which is
the result of NO signaling. This NO adduct on cysteine thiols (SNOs) can be investigated.
Abnormal S-nitrosylation can be found in various human diseases. Such is the case for
diabetes, where impaired function of NO synthase is prevalent. Diabetic peripheral
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neuropathy is a long term complication for diabetic patients and can lead to amputation;
this is theorized to be caused by lack of NO.25-26 It was found that diabetic patients
displayed an increase in red blood cell SNO-hemoglobin that displayed a defective release
of the NO adduct.27 Increased SNOs in the joints can be found with arthritis due to local
NO production, there is an increase in airway SNOs during pneumonia due to the induction
of iNOS, and the S-nitrosylation of MMP-9 can be found during stroke via the activation
of nNOS.27 A decreased amount of SNO-hemoglobin in red blood cells can be found in
pulmonary hypertension due to low oxygen saturation and a deacrease in SNO-proteins in
the lung can be found with pre-term birth due to decreased NOS expression.27
NO is already incorporated into various treatment plans for many cardiopulmonary
disorders, including for sickle cell disease, lung and heart transplants, and for newborns
with pulmonary hypertension.28 It has been used for biomedical devices, such as stents. A
stent with NO donor-containing liposomes has been shown to enhance endothelial cell
proliferation, while inhibiting smooth muscle cell proliferation for the purpose of fighting
against thrombosis and restenosis.29-30 NO can also be used to disperse biofilms from
accumulating on surfaces like catheters, implants, and on wounds.31
Due to NO’s role in wound repair, we have developed a novel NO generation
system based on copper-chitosan complexes that can potentially be used for the topical
generation of NO. Chitosan (derived from chitin) is a hydrophilic polysaccharide, made
from D-glucosamine and N-acetyl-D-glucosamine monomers bound through ß(1→4)
linkages.32 Chitosan is a biocompatible, biodegradable, non-toxic, and antimicrobial
polymer.33 As well, it is already used for various medical purposes such as wound
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dressings, tissue engineering, plastic surgery, and for drug delivery systems. 33 Here,
chitosan was chosen as the base matrix for the NO generation system due to its ability to
chelate various metal ions, including copper (Figure 1.2.4a). A study by Martinez et al.
showed that their nitric oxide releasing nanoparticles, a hydrogel/glass composite made
using chitosan, had beneficial effects on wound closure using mouse models.16 The
nanoparticles in this study used the glass properties of the composite to reduce nitrite to
NO. The NO produced was tested as a therapeutic strategy against superficial skin
infections; successful with both MRSA and MRSS bacterial strains.16

Figure 1.2.4a: Postulated structure for Chitosan-copper complex.
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1.2.5 Chitosan & Our Technology
Chitosan has previously been used in wound healing applications, mainly due to its
antimicrobial properties and its ability to perform as a stand-alone film, while being
supported by a backbone matrix (scaffolds), or as a gel. For instance, some success has
been found with a chitosan-based, film-forming gel containing an antibiotic in diabetic
mice wounds.34 Films, both made with chitosan alone and one with chitosan combined with
silver oxide nanoparticles were used in rat models. Both of these films outcompeted the
control group in a wound healing model, with a significant increase observed with the
modified chitosan.35 These results were especially apparent in the early phases of wound
healing. As well, chitosan-based scaffolds have shown an ability to enhance the process of
tissue regeneration when combined with immobilized growth factors.36 Chitosan is a highly
versatile biopolymer.
In this study, we present copper chitosan derivatives that produce NO by reducing
nitrite. During this process copper is oxidized to the +2 state.37 Glucose, a reducing sugar,
is added to the system to return copper to its +1 state.38-39 The overall process is
schematically shown in Figure 1.2.5a (i), with the postulated mechanism of NO conversion
is shown in Figure 1.2.5a (ii). Here, we made copper chitosan milli- and micro- sized
particles and demonstrated the NO production using a NO analyzer, a cell culture model
of wound healing, and by monitoring the intracellular NO target MMP-2 and -9.

11

(i)

(ii)

Figure 1.2.5a: Structures of Copper-Chitosan.
(i) Copper-chitosan’s pathway to making nitric oxide. Nitric oxide reduced from
nitrite via the oxidation copper (I) chitosan particles. The catalytic cycle is
completed by cupper being reduced by the oxidation of glucose to gluconic acid.
(ii) Postulated mechanism for NO production from nitrite and Cu+1. Nitrite (NO2-)
binds to Cu(I), where it becomes protonated. Water is released to produce a coppernitrosyl (Cu(I)-NO+). Cu(I)-NO+ is then reduced by the copper center and nitric
oxide is released. Cu(II) is reduced to Cu(I) to complete the catalytic cycle.
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1.3 Methods
Chitosan and copper-chitosan particles were successfully produced on the microand milli-size scale. Milli-size particles were used for experiments, including experiments
utilizing a Nitric Oxide Analyser to test for NO production, scratch assays to test for
cellular response in regards to cell growth, as well as a matrix metalloproteinase (MMP)
activity assays for a closer look at the NO effect at a cellular level. Chitosan and copperchitosan particles milli-particles will be respectively referred to as “chito” and “Cu-chito”
henceforth.
1.3.1 Copper-Chitosan Micro-Particle Preparation
Soft

lithography

and

molding

techniques

were

used

to

prepare

polydimethylsiloxane (PDMS) microfluidics apparatus, containing micro channels used to
control fluid flow. The apparatus is shown in Figure 1.3.1a (i). The design was adapted
from Sugaya et al.’s apparatus for micrometer-sized chitosan hydrogel beads.40
The PDMS mold was designed to have the dimensions of a glass microscope slide,
25.4 x 76.2 mm. To complete assembly, the mold was clamped between two microscope
slides using small binder clips. Tubing connected each channel to a syringe, via a 20G
needle connection. This full set up is shown in Figure 1.3.1a (ii).
The mold contained four micro channels placed in a cross formation, three for
reagents and one to act as an exit channel. Particles are formed by taking advantage of the
solubility properties of chitosan. Acid-dissolved chitosan solutions were made by
dissolving 0.05% (w/v) chitosan in 0.1 M acetic acid. This dilute chitosan solution was
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pumped down the vertical micro channel at a speed of 5 µL/min from a 10 mL syringe,
using a NE-300 Syringe Pump. This continuous flow was disrupted by 50 mM NaOH being
pumped by two other syringe pumps delivering NaOH solutions from 60 mL syringes into
their respective horizontal micro channel at a rate of 50 µL/min. Due to chitosan being
insoluble in basic pH levels, particles are essentially ‘pinched’ off from the original flow.
This forms reproducible particles under 5 microns in size. Copper chitosan micro-particles
were produced using the same protocol, but with copper chloride mixed with the chitosan.
A sample of micro-particles were reacted with 5-(dimethylamino)naphthalene-1sulfonyl chloride (dansyl chloride, DNSC) to produce fluorescent particles. To do this, a 3
mL solution of concentrated micro-particles made and suspended in 50 mM NaOH was
mixed with 1.5 mg of dansyl chloride and left at room temperature for 2 hours. The particles
were then spun down using a centrifuge on the lowest setting for two minutes, to form a
loose pellet. The supernatant containing excess dansyl was removed and the particles were
resuspended with 50 mM NaOH. This process was repeated and the particles were mounted
on microscope slide and sealed with a coverslip. A Zeiss Axiovert 200 microscope,
outfitted with a QImaging Retiga EX digital camera and a filter cube to accommodate
dansyl fluorescence (excitation filter, 350 nm, and emission filter, 500 nm-600 nm), was
used to obtain a fluorescent image.
The nucleophilic attack of dansyl chloride by the amine group of chitosan can be
seen in Figure 1.3.1b. The basic conditions can ensure the deprotonation of chitosan’s 1°
amine and aid with deprotonation of the dansyl-chitosan 2° amine.
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(i)

(ii)

Chitosan

NaOH

NaOH

Figure 1.3.1a: Particle-producing apparatus.
(i) PDMS microfluidics apparatus for chitosan micro-particle production. Three
reagent channels converge where the particles are formed and the resulting particle
suspension exits out of the exit channel.
(ii) Assembled microfluidics apparatus. The PDMS apparatus is clamped between two
glass slides. NaOH and a dilute chitosan solution is pumped into the apparatus via
syringe pumps and the resulting solution is collected.
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Figure 1.3.1b: Amine group of chitosan reacting with dansyl chloride. 2 hours RT, basic
conditions.
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1.3.2 Copper-Chitosan Milli-Particle Preparation
To produce copper chitosan milli-particles (Cu-chito), 2% (w/v) chitosan was
allowed to mix with an excess of copper chloride (CuCl2). The resulting Cu-chitosan
complex was dissolved with the addition glacial acetic acid to obtain a concentration of 1%
(v/v) acid. Excess Cu precipitate was allowed to separate from solution overnight and was
discarded. This wait period also allowed for any incorporated air bubbles to be removed.
Plain chitosan milli-particles (chito) were produced in an identical way but without adding
CuCl2, while the solution did not require removing precipitate, excessive air incorporated
adds difficulty while producing the particles. Thus, minimal mixing was used or the
solution was prepped and left to rest overnight.
The resulting viscous solution was dispensed via a 27G needle and a 10 mL syringe.
A NE-300 Syringe Pump dispensed the solution so drops fell in a dropwise manner into a
1 M NaOH solution. The resulting spherical particles, Cu-chito or chito, were thoroughly
rinsed with distilled water to remove excess base and left overnight in phosphate buffer
(pH 7.4, 0. 1M). This is to reduce particle pH closer to neutral. The particles were rinsed
again and dehydrated at room temperature. A count of 10 Cu-chito particles weighed in at
3.0 ± 0.03 mg with individual particles being <1 mm in diameter.
1.3.3 Nitric Oxide Detection
Authentic NO was detected using a Sievers NO analyzer (NOA, model 280i, GE
Analytical Instruments, Boulder, CO, USA). The NOA 280i was set up using the standard
NO2- measurement mode and standardized with NO2- according to manufacturer protocol.
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Chitosan milli-particles were added to an excess amount of dithiothreitol (DTT)
until the colour changed from dark purple to a pale yellow. This was done to reduce Cu(II)
to Cu(I), allowing Cu to be in an active state. The particles were washed with 100mL of
PBS to remove the excess DTT.
Chitosan (chito) or copper-chitosan (Cu-chito) particles of ~0.50 g, were placed in
22 mL screw cap vials, and were degassed under nitrogen for 5 minutes. 2 mL of 100 µM
sodium nitrite (NaNO2) ± 1 mM glucose was added. After allotted 15, 30, 45 or 60 minutes
of reaction time had passed, 1.5 mL of headspace gas was removed with a 2.5 mL syringe
(Hamilton 1000 Series Gastight Syringe) and injected into the NOA reaction vessel. The
NOA reaction vessel was set up as per manufacturer’s protocol. Control samples omitted
chitosan particles. Results were obtained via NOA peak area and compared to a standard
curve created by adding nitrite into I-3 (50 mg) in acetic acid (17.4M) described by Piknova
et al.41 All experiments were conducted in triplicate.
1.3.4 Cell Studies
Human retinal pigmented epithelium, ARPE-19 (ATCC® CRL- 2302TM) cells
were purchased from ATCC (Manassas, VA, USA) and grown in Dulbecco's Modified
Eagle Medium, Nutrient Mixture F-12 (DMEM/F12) supplemented with 10% fetal bovine
serum (FBS) and 1% penicilium/streptomycin antibiotic solution, incubated at 37 °C with
5% CO2.
ARPE-19 cells were used for scratch assays. They were plated in 6-well cell culture
plates and grown to approximately 90% confluence. Using a rubber ended cell scraper,
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cells were removed to form a linear artificial wound. Data was organized by wound size.
With the field of view taken into consideration, the average wound size was 1.8 mm2, with
the smallest being 0.8 mm2 and the highest being 4 mm2.
The milli-particle-bound Cu2+ was reduced with DTT, washed, and placed in
sterilized polydimethylsiloxane (PDMS) cups with 40 µL of nitrite (100 µM NO2–) ±
glucose (0.1 or 1.0 mM). The PDMS cups were produced following previous methodology
of our group, as described in Faccenda et al.42 The cups adhered to plate cover, and were
suspended in the medium with ~2 mm clearance from well bottom. They were placed in
the well approximately ~1 cm away from the center of the artificial wound (Figure 1.3.4a
(i, ii)). NO as well as other gases like O2, H2S etc. freely diffuse through the PDMS, while
salts and hydrophilic compounds like the nitrite and glucose do not.42 Control samples refer
to PDMS cup containing nitrite solution only.
A Zeiss Axiovert 200 microscope, outfitted with a QImaging Retiga EX digital
camera, was used to take DIC cell images. The number of cells in the scratch wound area
at 0 and 48 hours were compared and the net number of new cells was reported (Equation
1.3.4a). Images were obtained at 0 and 48 hours and the cell counts were calculated using
Image-J software.
Equation 1.3.4a: 𝑵𝒆𝒕 𝒄𝒆𝒍𝒍 𝒈𝒓𝒐𝒘𝒕𝒉 = 𝑪𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕𝟒𝟖 𝒉𝒓𝒔 − 𝑪𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕𝟎 𝒉𝒓𝒔
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(i)

(ii)
Artificial Wound

PDMS cup containing:
Particles + Nitrite ± Glucose

Figure 1.3.4a: Scratch assays with ARPE-19 mammalian cell culture.
(i) Particles with nitrite ± glucose confined by PDMS cups, adhered to plate cover,
were suspended in the medium with ~2 mm clearance from well bottom.
(ii) An illustration of the relative position of the PDMS cups with respect to the
artificial wound, which spanned the vertical length of each well.
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1.3.5 Matrix Metalloproteinase (MMP) Activity
Gelatin zymography was utilized to identify matrix metalloproteinase-2 (MMP-2,
gelatinase A) and -9 (MMP-9, gelatinase B). This technique can be used to identify the
type of gelatinase, relative amount, and activation status (latent vs active).43 Zymography
works by impregnating the resolving layer of SDS-PAGE gels with the peptide substrate
of the enzyme of interest. Protein in non-reducing conditions is electrophoresed. The gel is
then incubated with the cofactors necessary for reaction to occur. Gelatinase activity is
localized where the protein is present and white bands can be viewed upon distaining, in
the areas where the gelatin was hydrolysed.
A standard gelatin zymography protocol (Abcam) was followed.44 ARPE-19 cells
were grown in 10 cm plates to 60% confluence. Using the width of a rubber ended cell
scraper (1.7 cm), a vertical wound was made down the length of the plate. Removed cells
and media was washed off with sterile PBS then grown with DMEM/F12 media lacking
FBS. Cells were treated with 3 PDMS cups filled with their respective treatments, cups
with 40 µL of nitrite (100 µM) ± glucose (1.0 mM) ± particles. After 48 hours, cell media
was collected and analyzed via protocol. In overview: samples are run using non-reducing
sample buffers on an SDS-PAGE gel co-polymerized with gelatin, SDS is washed out of
the gel and it is incubated for 24 hours with the cofactors necessary to allow for gelatinase
activity. The gel is then stained and destained, areas where the gel becomes clear is where
the gelatin was hydrolysed by the enzymes. The bands appear as clear bands on blue
background.
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The resulting band area of each sample was processed through Image-J software.
Values reported were normalized to the control data.
1.3.6 Statistical Analysis
Data was expressed as mean ± standard deviation. Two-tailed t-tests determined
statistically significant differences at a 95% confidence interval. Statistical significance is
determined by t being greater than the critical value (t > c.v.).
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1.4 Results
1.4.1 Copper-Chitosan
The microfluidics apparatus was successfully used to make particles <10 microns
in size with an apparent average of around 3 μm. The particles themselves are spherical
and can be produced with and without copper. Shown in Figure 1.4.1a (i) is an image of
copper-chitosan micro-particles made fluorescent by dansyl chloride. The particles are not
considered robust, attempts to neutralize the pH result in dissolved particles and when left
in their original basic media they aggregate relatively quickly. They are easy to produce
when following protocol, however obtaining a large number of concentrated particles can
take several days depending on the quantity desired. Immediate, unconcentrated particle
solutions is suitable for imaging. Changing variables can change particle shape. For
example, increasing the concentrations of chitosan produced varying shapes, such as longer
cylindrical fibers (not shown).
The milli-particles, chito and Cu-chito, were used in experiments for NO detection,
as well as for cell studies. The particles can maintain their integrity over several rounds of
reduction with DTT and handling, thus they are considered relatively robust. In Figure
1.4.1a (ii), there is visible swelling while the particles are hydrated, however upon
dehydration they return to their original size. This swelling does not compare to the fully
hydrated particles prior to being de-hydrated. These particles can be seen in Figure 1.4.1a
(iii-iv). After particles are reduced with DTT and washed, they can be left in a N2-purged
vial for several days before visible oxidation (green to blue colour change) is seen. In
comparison, particles exposed to air will re-oxidize overnight. The shelf life of reduced
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particles could be increased by storing them in an inert atmosphere. Particles used for
experiments were utilized immediately after the reduction and subsequent washes.
While milli-sized particles were successfully formed and utilized, copper-chitosan
can be manipulated in a variety of ways to increase functionalization and application
potential. Copper-chitosan micro-particles were produced using microfluidic techniques
and the milli-particles can be ground into a fine powder. This could allow for incorporation
into gels, creams, eye drops, wound washes, or other forms of topical application. Copperchitosan can also be made into a film (not shown), for incorporation onto biomedical
devices or wound dressings. As well, it can be fixed onto gauze (shown), for uses as a
wound dressing; preliminary gauze NOA 280i experiments showed that copper gauze is
capable of NO release (not shown). Figure 1.4.1a (v) shows some of these forms of
chitosan, including milli-particles, chitosan powder, and copper-chitosan fixed onto gauze.
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(i)

(ii)

10 microns

(iii)

(iv)

Figure 1.4.1a (i-iv): Various forms of chitosan and copper chitosan.
(i) Fluorescent microscope image of copper-chitosan micro-particles, taken after a
reaction with dansyl chloride.
(ii) Left: copper-chitosan milli-particles. Right: copper-chitosan milli-particles after
Cu2+ was reduced to Cu1+ by 0.5 M DTT in H2O; the particle size increases
significantly due to hydration during the reduction process.
(iii)Freshly prepared chitosan (chito) milli-particles, fully hydrated and not yet dried
for use. Shown in 100 mL beaker.
(iv) Freshly prepared copper-chitosan (Cu-chito) milli-particles, fully hydrated and not
yet dried for use. Shown in 100 mL beaker.
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(v)
(A1)

(A2)

(A3)

(B1)

(B2)

(B3)

Figure 1.4.1a (v): Various forms of chitosan and copper chitosan.
(v) (A1) Chitosan milli-particles
(A2) Chitosan powder
(A3) Untouched gauze
(B1) Copper-chitosan milli-particles
(B2) Copper-chitosan milli-particles ground into a powder
(B3) Copper-chitosan fixed onto gauze.
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1.4.2 Nitric Oxide Detection
The Sievers NOA 280i was used to demonstrate that the Cu-Chito milli-particles ±
glucose can produce authentic NO. In these experiments, the milli-particles + nitrite ±
glucose were placed in degassed gas-tight vials, three vials at each time point, and each
vial was only sampled once at 15 minute intervals up to 60 min. The graphical results at
the various time points can be seen in Figure 1.4.2a (i). Peak data was converted to nmol
amounts of NO per gram of milli-particles and adjusted for the total headspace of each
reaction vial. Each sample, including the control samples, contained 100 µM NO2– ± 10
mM glucose. In Figure 1.4.2a (ii) the data is represented as the rate of NO produced/min.
As indicated in Figure 1.4.2a, the milli-particles did produce NO. The level of NO detected
by Cu-chito treatments in the presence of glucose did not result in statistically significant
differences in comparison to the Cu-chito treatments without glucose present.
The NO production rate plot (Figure 1.4.2a (ii)) was more revealing of the reaction
dynamics. The maximum rate of NO production was ~ 1.40 nmol/min (Cu-chito) and 1.08
nmol/min (Cu-chito + glucose). Beyond this point the NO production rate steadily
decreased to ~0.24 nmol/min (Cu-chito) and ~0.27 nmol/min (Cu-chito + glucose).
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Figure 1.4.2a: NO signal detected by chitosan milli-particles as observed by the
Sievers NOA 280i. Active particles were left to react with 100µM nitrite ± 1.0mM glucose,
with gas samples were taken every 15 minutes from separate vials i.e. each vial at each
time point was sampled only once.
(i) Values represent nmoles of NO produced in the total headspace (20 ml) of reach
reaction vial, adjusted for particle mass.
(ii) The data expressed as rate of NO produced by Cu-chito and Cu-chito + glucose
over sampling time.
28

1.4.3 Cell Studies
Scratch assays were performed in order to simulate an in vitro wound model, in
order to test our novel NO releasing particles. They can provide insight into cell–matrix
and cell–cell interactions, cell migration, cell proliferation, and can mimic cell migration
during wound healing. The data collected here provides the net number of new cells in the
wound area, with the data collected at 0 hours and 48 hours. The various cell treatments,
of nitrite ± Cu-chito or chito, and ± glucose, were prepared into a PDMS cup and placed
with the cell for the duration of the 48 hours.
The scratch assay experiments were conducted using ARPE-19 mammalian cell
culture. The reagent controls (nitrite ± glucose) and the NO generation system (chito or
Cu-chito with nitrite ± glucose) were isolated from the cells by placing them inside of
PDMS cups (Figure 1.3.4a (i, ii)) which are impermeable to ionic and hydrophilic
molecules but allow gases such as NO to pass through. Table 1.4.3a displays the number
of new cells grown in the wound for each treatment type.
Overall, the Cu-chito showed an increase in number of cells in the wound, with
around ~200-300 new cells more than the controls. Using a 95% confidence interval, this
is considered statistically significant. This result is very promising, especially since the
chito particles without copper only showed around 0-40 new cells in comparison to the
controls, which is statistically insignificant. To visualize the effect of the Cu-chito particles,
Figure 1.4.3a compares 0 hours to 48 hours on the number of cells, for data with a wound
size of 1.8 mm2.
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The data in Table 1.4.3a also reveals the difference between having glucose present
or absent. With glucose, Cu-chito treatments showed an increase of 152% more cells in the
wound in comparison to control groups, while Cu-chito treatments with nitrite alone
showed 130% more cells in the wound. In comparison to each other, the Cu-chito with
glucose treatments displayed a significant increase of ~118% more cell cells in the wound
in comparison to treatment of Cu-chito and nitrite. However, Cu-chitosan with 0.1 mM
glucose vs. 1 mM glucose were statistically insignificant in comparison to each other. This
is not completely unexpected, since both their concentrations are large; this indicates that
0.1 mM or less of glucose may be sufficient to elicit a similar response.
We also wanted to see if the effect of particle-generated NO would have a different
effect depending on the size of the manually-obtained wound. To do this we created a
distribution of pseudo-wounds wound areas ranging from 0.8 mm2 to 4.0 mm2. To further
analyze the effect wound size had on the effectiveness of the Cu-chito treatments, the data
was reorganized by the wound size and further analyzed with two-tailed t-tests for
statistical significance. The control and Cu-chito data is reorganized by wound size in
Figure 1.4.3b, with the corresponding statistical information shown in Table 1.4.3b.
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Table 1.4.3a: Scratch assay results with ARPE-19 mammalian cell culture. Various
treatment types of chitosan milli-particles and the net number of new cells after 48 hours.
Statistical comparison is to the control data. Two tailed t-test: statistical significance is
determined by t being greater than the critical value (t > c.v.). Number ‘n’ refers to number
of data values used.
Treatment Type:

New Cell Count:

Control (n=72)

588.6 ± 181.1

Cu-Chito (n=54)

763.9 ± 231.3

Cu-Chito + 0.1 mM Glucose (n=48)

898.0 ± 219.4

Cu-Chito + 1.0 mM Glucose (n=54)

874.9 ± 173.7

Chito (n=24)

621.7 ± 154.5

Chito + 0.1 mM Glucose (n=24)

610.0 ± 257.0

Chito + 1.0 mM Glucose (n=24)

583.1 ± 215.4
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95% Confidence
Interval:

Significant
(4.8 > 2.0)
Significant
(8.3 > 2.0)
Significant
(8.9 > 2.0)
Not Significant
(0.8 < 2.0)
Not Significant
(0.4 < 2.0)
Not Significant
(-0.1 < 2.0)

(i) Nitrite Control

(ii) Cu-Chito + Nitrite

Figure 1.4.3a (i-ii): Representative scratch assay images for pseudo-wounds of 1.8
mm2 in size. Reported as the difference in number of cells at 0 and 48 hours, as counted
by ImageJ:
(i) Nitrite Control sample- net number of new cells: 588.6 ± 181.1 cells
(ii) Cu-Chito + Nitrite treatment- net number of new cells: 763.9 ± 231.3 cells
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(iii) Cu-Chito + Nitrite + 0.1 mM Glucose

(iv) Cu-Chito + Nitrite + 1.0 mM Glucose

Figure 1.4.3a (iii-iv): Representative scratch assay images for pseudo-wounds of 1.8
mm2 in size. Reported as the difference in number of cells at 0 and 48 hours, as counted
by ImageJ:
(iii)Cu-Chito + Nitrite + 0.1mM glucose treatment- net number of new cells: 898.0 ±
219.4 cells
(iv) Cu-Chito + Nitrite + 1.0mM glucose treatment- net number of new cells: 874.9 ±
173.0 cells
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1400

New Cell Growth After 48 Hours

1200

1000

800
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400

200

0
0.8-1.39

1.4-1.59

1.6-1.9

Wound Size
Control

Cu-Chito

2-2.39

2.4+

(mm2)

Cu-Chito + 0.1mM Glucose

Cu-Chito + 1.0mM Glucose

Figure 1.4.3b: Cu-chito scratch assay results, organized by wound size. The Cu-chito
(nitrite ± glucose) data sets are compared to the respective control (nitrite) data. The net
number of cells in the wound at 48 hours is shown, with the data sets organized by
increasing wound size analyzed. (Note: * indicates significance in comparison to the
respective control data at a 95% confidence interval; NS = not significant. Statistics
displayed in Table 1.4.3b)
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Table 1.4.3b: Statistics for scratch assay results, with data organized by wound size.
Various treatment types of chitosan milli-particles and the net number of new cells after 48
hours. Statistical comparison is to the respective control data. Two tailed t-test: statistical
significance is determined by t being greater than the critical value (t > c.v.). Number ‘n’
refers to number of data values used.
Wound Size:
0.80-1.39 mm2

1.40-1.59 mm2

1.60-1.90 mm2

2.00-2.39 mm2

2.40+ mm2

Treatment Comparisons:
Control (n=21)
Cu-Chito (n=13)
Control (n=21)
Cu-Chito + 0.1 mM Glucose (n=10)
Control (n=21)
Cu-Chito + 1.0 mM Glucose (n=13)
Control (n=13)
Cu-Chito (n=7)
Control (n=13)
Cu-Chito + 0.1 mM Glucose (n=7)
Control (n=13)
Cu-Chito + 1.0 mM Glucose (n=14)
Control (n=12)
Cu-Chito (n=16)
Control (n=12)
Cu-Chito + 0.1 mM Glucose (n=10)
Control (n=12)
Cu-Chito + 1.0 mM Glucose (n=13)
Control (n=11)
Cu-Chito (n=9)
Control (n=11)
Cu-Chito + 0.1 mM Glucose (n=8)
Control (n=11)
Cu-Chito + 1.0 mM Glucose (n=8)
Control (n=14)
Cu-Chito (n=11)
Control (n=14)
Cu-Chito + 0.1 mM Glucose (n=13)
Control (n=14)
Cu-Chito + 1.0 mM Glucose (n=6)
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95% Confidence
Interval:
Not Significant
(0.4 < 2.0)
Significant
(2.5 > 2.00)
Significant
(3.1 > 2.0)
Significant
(2.8 > 2.1)
Significant
(3.5 > 2.1)
Significant
(4.0 > 2.0)
Significant
(3.2 > 2.0)
Significant
(3.0 > 2.0)
Significant
(4.9 > 2.0)
Significant
(3.7 > 2.1)
Significant
(5.8 > 2.1)
Significant
(5.3 > 2.1)
Significant
(3.9 > 2.0)
Significant
(5.3 > 2.0)
Significant
(5.0 > 2.1)

1.4.4 Gelatin Zymography for MMP Activity
Samples processed by gelatin zymography immediately after the 48 hour treatments
can be seen in Figure 1.4.4a (i-ii). With the area of each band normalized to the nitrite
control, the results show a 60% increase in MMP activity after Cu-chito and Cu-chito +
glucose treatments. The 73 kDa band was used for this measurement due to the clear affect
that the particle treatments displayed. With the nitrite control being set to 100 ± 13%, the
water control compared at 99 ± 26%. Cu-chito displayed 164 ± 26% and Cu-chito with
glucose added displayed 160 ± 5% of the nitrite control. The quantification of the band
density is summarized in Figure 1.4.4a (iii).
Further differences between the control samples and the copper particle samples is
the presence of more bands displaying gelatinase activity. The copper particle treatments
appear to induce other gelatinase enzymes, with a somewhat defined band appearing at 86
kDa. This band was not seen in comparison to control samples. The molecular weight
(MW) of this band, along with the prominent 73 kDa band, was calculated using the
molecular weight (MW) ladder, which appears on the left of each gel image. This was done
using a log(MW) Vs Rf graph (not shown).
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(i)
100 kDa
86 kDa
75 kDa

73 kDa

63 kDa
Cu-Chito

Cu-Chito

Cu-Chito
+ Glucose

(ii)
100 kDa

75 kDa
73 kDa
63 kDa
Nitrite
Control

Nitrite
Control

H2O
Control

Figure 1.4.4a (i-ii): MMP activity via gelatin zymography.
(i) Zymography gels of copper-chitosan milli-particle treatments. Left to right, the gel
lanes contain prestained protein ladder, followed by two Cu-chito with nitrite
samples and one Cu-chito with nitrite and glucose sample, run in duplicate.
(ii) Zymography gels of control treatments. Left to right, the gel lanes contain
prestained protein ladder, followed by two nitrite control samples and one water
control sample, run in duplicate.
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(iii)
2.5

1.00 ± 0.13

0.99 ± 0.26

1.64 ± 0.20

Normalized Band Area

2

1.60 ± 0.05

*
*

1.5

NS
1

0.5

0
Nitrite Control (n=4)

Water Control (n=3)

Cu-Chito + Glucose
(n=3)

Cu-Chito (n=3)

Treatment Type

Figure 1.4.4a (iii): MMP activity via gelatin zymography.
(iii)Band densities of bands located at 73 kDa, calculated using ImageJ. Data is
normalized to the nitrite control data. Samples were processed immediately after
their respective 48 hour treatments. (Note: * indicates significance in comparison
to nitrite control data at a 95% confidence interval; NS = not significant)
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1.5 Discussion
This is a study into the production of a novel NO releasing particles at the milli and
micro scale, using chitosan as a matrix for a copper catalyst. The milli-sized particles were
tested for the authentic production of NO using the NOA 280i and underwent testing in an
in vitro wound healing model. In addition to scratch assays, matrix metalloprotease
enzymes were chosen as an extracellular target to observe the effect of the NO treatments.
1.5.1 Nitric Oxide Detection
NO production was detected by taking readings of the headspace gas of samplecontaining vials. Copper containing particles successfully produced detectable NO gas
over the course of an hour, while controls and particles lacking in a copper aspect produced
comparatively minimal signals.
Beyond this, there are a couple of interesting takeaways that the data provides. First,
the presence of glucose had a statistically insignificant effect. Glucose neither helps nor
hinders the NO production potential exhibited by the particles. This may be attributed to
the short time scale that the reaction was monitored and overall does not disprove the theory
that glucose could aid in catalytic turnover over time.
As well, while the copper samples give consistent readings in the range of 15-20
nmol/g, the rate of NO production over time decreases over the course of the hour. One
reason for this could be the closed system that the readings were taken. In this closed
system, NO could be reacting with Cu2+ and being converted back to nitrite; this has been
demonstrated by Sarma & Mondal.45 Since NO(g) (the detected species) is in equilibrium
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with NO(aq) this leads to a suppressed value of the NO produced by the particles, in
comparison to its maximum potential. This equilibrium is shown in Equation 1.5.1a. This
situation is not expected to occur in the wound healing cell model used, as the NO(g)
generated would diffuse away to induce cellular signaling. With NO(g) being removed from
the equation, the reaction would be pushed towards the product side.

Equation 1.5.1a:
1.5.2 Cell Studies
Interesting patterns arose when comparing wound size. The graph (Figure 1.4.3b)
shows how the two glucose treatments remain similar at every size point. The Cu-chito
remains competitive with glucose treatments for sizes 1.4-1.9 mm2. If wound sizes
remained in this range, the effect of glucose would remain inconclusive. At sizes 2 mm2
and higher, with more room for cells to grow, glucose treatments show increased number
of new cells in the wound suggesting that, as we postulated, sustained NO production can
be maintained as long as there is sufficient glucose present to recycle the oxidized copper.
Unfortunately, we could not demonstrate the sustained NO released from the particles with
the closed discontinuous system for NOA detection of NO. It is possible to use the NOA
280i for live NO readings and this has been done46, however would require building a gas
tight chamber for the cells to incubate, with 5% CO2 incoming and all air being fed into
the machine for NO detection.
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The effect of glucose is seen in this data. Cu-chito treatments that combined nitrite
and glucose had a significant increase in new cells in the wound in comparison to
treatments with nitrite alone. Cu-chito without the addition of glucose grew an average of
170 more cells per experiment than the control experiments. Whereas Cu-chito with the
presence of glucose grew an average of 300 more cells per experiment, compared to the
nitrite control (data can be observed in Table 1.4.3a). This is determined as statistically
significant, with a two tailed t-test comparing these values (data not shown). Thus, it
supports our hypothesis that the addition of glucose aids in the production of NO.
1.5.3 MMP as a NO Sensor
The technique of gelatin zymography is used to identify the activity of MMP-2 and
MMP-9, both of which have gelatinase activity. Due to the correlations between NO and
MMP activity, this was chosen to observe the changes that the Cu-chito treatments can
enact on an enzymatic level. Zymography gels can theoretically be used to identify the type
of gelatinase, relative amount, and activation status (latent vs active).43 In order to
accurately identify activation status, an internal standard is required. Options for this
include conditioned medium from HT1080 human fibrosarcoma cells, which contains
MMP-2 (72kDa) and MMP-9 (92kDa).43 If these cells undergo treatment, the media can
also contain active MMP-2 (62 kDa), another option is using purified protein, if available.
Active MMP-9 is 82 kDa.
There are also intermediate inactive forms of MMP-2 (64 kDa) and MMP-9 (85
kDa), and the possibility of low-weight active forms of MMP-2 (45 kDa) and MMP-9 (67
kDa). Viewing all these forms is possible do the SDS in the gel and in the sample buffer
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that works to unfold the protein in a way that exposes the active site and allows for
activity.43 The intermediate inactive form is found when samples contain endogenous
tissue inhibitors of metalloproteinases (TIMPs); this band would be difficult to isolate due
to the small difference in size to the respective active species. Low-weight active forms
become an issue when protein samples are purposefully treated to obtain the active forms
and are overexposed to the treatment.43 Since our samples are not obtained from a tissue,
nor are they purposely treated, bands in these locations are not expected to occur.
The copper containing samples displayed a marked increase in the protein
observed. The band that best observes this change was the one seen at 73 kDa, since this
band also appeared in the control samples (Figure 1.4.4a (i)). This is likely inactive MMP2, based on size. Copper samples also displayed a distinctive peak at 86 kDa which could
correspond to a form of MMP-9 (Figure 1.4.4a (i)). To truly confirm the identity of the
present enzyme, the use of an internal standard may be necessary. Otherwise techniques
such as immunoblotting could be used. In terms of true quantification, ELISA assays would
be the gold standard. To determine if expression levels is the cause of increase in MMP
activities, reverse transcription polymerase chain reaction (RT-PCR) would have to be
utilized.47-48
The mechanism of change that NO effects in MMP’s can vary by MMP type or on
the cell or tissue type in question. Studies suggest that NO effects activation of MMP’s
through S-nitrosylation.49 Some research on human cells include rheumatoid synovial cells,
where NO has be found to increase the expression levels of MMP-2.50 It was found that
MMP-2 is regulated by NO in fibrosarcoma epithelial cancer cells.51 MMP-9 in human
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placental tissue is activated by NO; with patients with gestational and pre-existing diabetes
mellitus having reduced activity of the enzyme, due to the reduction of NO.52 NO effects
MMP-9 in airway epithelial cells through an expression and activation; the use of NO
donors in this study was found to promote wound repair through these methods.53
While its is entirely possible that the ARPE-19 cells are reacting to the NO
stimulation through an increase in MMP expression, the experimental work done cannot
confirm this mechanism of action. With the evident increase in activity, S-nitrosylation
activation is the simplest explanation.
In regards to this project itself, the fact that these changes are observed at the 48hour mark indicate that the nitric oxide supplement via copper chitosan particles is
providing long-lasting effects.

43

1.6 Conclusion
By complexing copper with chitosan polymer, nitric oxide releasing derivatives
have been developed. Copper-chitosan micro- and milli- particles were produced using
microfluidic techniques. Authentic nitric oxide production from copper-chitosan milliparticles was observed using the Seivers Nitric Oxide Analyzer 280i. In vitro scratch assays
with the ARPE-19 cell line resulted in an increase of cell new cells in the wound after
treatment with the copper-chitosan milli-particles, as well as an even higher increase in cell
new cells by supplementing glucose in the particle treatment. Using the activity of MMP
proteins as a NO sensor resulted in Cu-chito treatments showing a 60% increase in cellular
enzymatic activity in comparison to controls; the influence of NO can be observed at least
up to the end of the 48-hour treatment.
There are many applications for the technology presented here. The size of the nitric
oxide releasing micro-particles would allow for use in gels, creams, eye drops, wound
washes, or other topical applications for a wound. Copper chitosan could be incorporated
directly onto biomedical devices, or a wound dressing, gauze or otherwise. Our technology
utilizes a minimal number of easily accessible, low-cost, components, as well as a
minimally complex system for forming particles that can easily be adapted to an industrial
setting. This puts our technology at a clear advantage in comparison to other NO releasing
systems, for example, those that use NO donor compounds or other drugs that have to be
independently synthesized.
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1.7 Future Directions
Future work that could benefit this project includes battling the logistics of taking
live readings of NO output over a greater period of time. Being able to assess the quantity
of NO that the mammalian cells are utilizing versus how much is being outputted total
would benefit in assessing the concentration of NO that would benefit the cells without
releasing a concentration that becomes needlessly toxic. In addition, monitoring other
extracellular effects would add useful insights to the effects of the treatments. The
complications with this include the ability to measure endogenous proteins. Past work in
this regard includes Western blot assays utilizing antibodies (Santa Cruz Biotechnology)
that target fibroblast growth factor 2 (FGF-2) and vascular endothelial growth factor
(VEGF), to no success in identifying the proteins at endogenous levels. Optimizing these
experiments or pursuing different routes, including routes that take a closer look at MMP
levels, is a possible future direction. Performing a Western blot while probing for Snitrosocysteine residues may be of interest.
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CHAPTER 2: Study into an Allosteric Site of
\\\\\\

S-nitrosoglutathione Reductase (GSNOR)

46

\

2.1 Chapter Summary
S-nitrosoglutathione (GSNO), an endogenous S-nitrosothiol (SNO), plays a
prominent role in nitric oxide (NO) signaling and bioavailability. S-nitrosoglutathione
reductase (GSNOR) is the enzyme responsible for its metabolism. Due to this, GSNOR’s
activity has a strong influence on SNO-protein levels. As such, furthering the
understanding of GSNOR’s regulatory mechanisms is of great interest. Our group has
noted a sigmoidal deviation in GSNOR’s steady state kinetics, in regards to GSNO
concentrations. Our kinetic analysis yields a sigmoidal curve with a Hill coefficient (n) of
1.49 ± 0.037; indicating positive allostery. Molecular docking (MD) simulations were
performed and implicated the amino acid residues Gly321, Lys323, Asn185, and Lys188
in the binding of an allosteric GSNO; in a location adjacent to GSNOR’s structural zinc
atom. To further these studies, time-resolved electrospray (TRESI) microfluidics set up
was utilized to perform hydrogen / deuterium exchange (HDX) mass spectrometry (MS)
experiments. With a two second HDX reaction time, the peptides containing the residues
Gly321, Lys323, and Lys188 displayed a decrease in deuterium uptake of 1.4%, 1.4%, and
0.4%, respectively. These changes were calculated as the difference in deuterium uptake
after the inclusion of GSNO in the GSNOR protein solution. This offers insight into the
interactions of GSNO at these amino acid residues and ultimately supports the location of
the allosteric site proposed by the MD studies.
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2.2 Introduction
2.2.1 GSNOR as ADH5
S-nitrosoglutathione reductase (GSNOR) is an alcohol dehydrogenase class-3
(AHD-3) enzyme encoded by the ADH5 gene, located on the reverse strand of
chromosome 4 (4q23 – chr4:99993567 – 10000985).54 Sometimes referred to as ADH5,
GSNOR has several other aliases and functions beyond its role in metabolizing the
substrate S-nitrosoglutathione (GSNO).55
Another main role of GSNOR is to act as a glutathione-dependent formaldehyde
dehydrogenase (GSH-FDH, FALDH).56 ADH5 is critical in the metabolic elimination of
formaldehyde.

Formaldehyde

can

react

with

glutathione

to

form

S-

(hydroxymethyl)glutathione (HMGSH) and from there ADH5 can oxidise it to Sformylglutathione, this process is shown in Figure 2.2.1a. S-formylglutathione can then
go on to undergo hydrolysis via S-formylglutathione hydrolase to produce formic acid and
to regenerate GSH.57 ADH5 requires the cofactor NAD+ for this function and results in the
formation of NADH, the cofactor required for GSNO reduction.
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Figure 2.2.1a: ADH5 and its role in formaldehyde detoxification. GSH reacts with
formaldehyde to produce HMG. ADH5 can then oxidise HMGSH to form Sformylglutathione. S-formylglutathione is then hydrolyzed via S-formylglutathione
hydrolase to reobtain GSH (not shown).
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Other synonyms for GSNOR include chi polypeptide, and AHDX, FDH, and HELS-60p. Despite being an alcohol dehydrogenase, ADH5 has a low affinity for ethanol,
preferring instead to perform the oxidation of long-chain primary alcohols (with a
preference with a double bond located in the β position), complex alcohols of high
molecular weight, and omega-hydroxy fatty acids.58
GSNOR is found in both prokaryotic and eukaryotic organisms, and highly
conserved across most vertebrate species.59 GSNOR plays an important role in plants, the
enzyme is necessary for normal growth and development.60 Arabidopsis thaliana plants
occupies much of the plant GSNOR research available, however there has also been work
involving peas (Pisum sativum L.), pepper (Capsicum annuum L.), sunflower (Helianthus
annuus L.), the fungus Plasmopara halstedii, as well as maize and rice.60 GSNO’s role in
S-nitrosothiol formation, the formation of reactive nitrogen species (RNS), and its ability
to influence NO homeostasis, plants are at a severe disadvantage if they display atypical
GSNOR activity or expression.
In human tissue, ADH5 displays ubiquitous expression. Notably, GSNOR is found
in the endometrium (RPKM 69.1), kidney (RPKM 68.7), fat (RPKM 61.5), liver (RPKM
57.4), prostate (RPKM 62.0), ovary (RPKM 49.2), and esophagus (RPKM 53.3).61
GSNOR is a cysteine rich homodimer, found in the nucleus and cytoplasm.62 It is a
metalloprotein, containing two zinc atoms per monomer, while both are in the catalytic
domain, only one is involved in catalysis while the other is considered a structural zinc.
The molecular weight of a monomer is 39,724 kDa consisting of 374 amino acids
(UniProtKB identifier: P11766) translated from 9 exons.58 The amino acids involved with
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binding are highly conserved, especially Glu68 and Arg379 since they are important to the
catalytic mechanism.58, 63 Cys45, His67, Glu68, and Cys174 are involved in the binding of
the catalytic zinc atom while Cys97, Cys100, Cys103, and Cys111 bind the structural
zinc.64 Amino acids Ala302-Gln307 are involved in the diner interface interactions.65 It is
the amino acids of the interacting interface, and in the coenzyme binding domain, that
protect the integrity of the homodimer; variations here prevent the formation of
heterodimers with other alcohol dehydrogenase enzymes.65-66 The dimeric structure and
the dimeric interface of human GSNOR is shown in Figure 2.2.1b, while the amino acids
involved in the binding of the zinc atoms are displayed in Figure 2.2.1c.
These amino acid labels are consistent with the Met1-Ile374 sequence for human
GSNOR used for the recombinant wild type GSNOR sequenced for this project. The full
sequence can be found in Appendix Figure A.1.
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Figure 2.2.1b: GSNOR dimeric crystal structures. GSNOR crystal structure images
(PDB ID: 3QJ5) modified using UCSF Chimera software. Dimerized wild type GSNOR
crystal structure. Red circles highlight structural zinc atoms, blue circles highlight catalytic
zinc atoms. The left-sided monomer is shaded grey to call attention to the dimer interface
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(i)

(ii)

Figure 2.2.1c: Zinc binding of GSNOR.
(i) Active site pocket with catalytic zinc. Cys45, His67, Glu68, and Cys174 are
highlighted. Image acquired from the left-sided monomer, relative to the structures
displayed in Figure 2.2.1b.
(ii) Structural zinc with Cys97, Cys100, Cys103, and Cys111 highlighted. Image
acquired from the left-sided monomer, relative to the structures displayed in Figure
2.2.1b.
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2.2.2 GSNO & GSNOR in the Human Body
The two best substrates for ADH5 are HMGSH and GSNO. With the catalytic
efficiency of the metabolism of GSNO almost twice of that for HMGSH, GSNO is
considered the best substrate for the enzyme.67
The metabolism of GSNO begins with the reductase activity of GSNOR. The first
step involves GSNOR reducing GSNO to the unstable intermediate N-hydroxysulphenamide (GSNHOH) (Equation 2.2.2a). When GSH is present, GSNHOH will react
to form the glutathione dimer GSSG, with hydroxylamine (NH2OH) as a side product
(Equation 2.2.2b). Without GSH present, the unstable GSNHOH will spontaneously
rearrange to form glutathione sulphinamide (GSONH2) which can then be hydrolysed
under acidic conditions to obtain glutathione sulphinic acid (GSOOH) and ammonia
(NH4+) (Equation 2.2.2c).68 The overall reaction is irreversible67, and the structural
changes described are shown in Figure 2.2.2a.
𝑮𝑺𝑵𝑶𝑹

Equation 2.2.2a: 𝑮𝑺𝑵𝑶 + 𝑵𝑨𝑫𝑯 + 𝑯+ →
Equation 2.2.2b: 𝑮𝑺 − 𝑵𝑯𝑶𝑯 + 𝑮𝑺𝑯 →
Equation 2.2.2c: 𝑮𝑺𝑶𝑵𝑯𝟐 + 𝑯𝟐 𝑶 →
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𝑮𝑺 − 𝑵𝑯𝑶𝑯 + 𝑵𝑨𝑫+

𝑮𝑺𝑺𝑮 + 𝑵𝑯𝟐 𝑶𝑯
𝑮𝑺𝑶𝑶𝑯 + 𝑵𝑯+
𝟒

Figure 2.2.2a: Reaction products of GSNO metabolism. GSNO is reduced to GSNHOH
by enzyme GSNOR and cofactor NADH. Unstable GSNHOH has two routes of action,
with GSH present, GSSG will be formed. Without GSH, GSNHOH will rearrange to
GSONH2 which can hydrolyse under acidic conditions to GSOOH.
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The GNSO products are determined on the cell redox potential related to the GSH
levels. GSH levels can vary wildly due to its antioxidant activity, under oxidative stress
GSH levels are decreased.68 This results in GSONH2 and subsequently GSOOH. Under
physiological conditions, GSH occurring in the millimolar range can result in the formation
of GSSG and NH2OH.39
As previously stated, the regulation of GSNO correlates to cellular NO
homeostasis, S-nitrosothiol formation, and the formation of reactive nitrogen species
(RNS). This is due to GSNO acting as endogenous ‘sink’ or ‘reservoir’ of bioavailable NO.
While NO production by NOS enzymes are co-localized with target proteins, the transfer
of NO groups to on cysteine residues allows NO to propagate signal transduction pathways
throughout the cell.69 As GSNO is the most abundant small molecular weight SNO, its
metabolism by GNSOR is of high consequence.
In particular, the inflammatory lung diseases of cystic fibrosis and asthma are both
worsened by the upregulation in GSNOR activity. This, in turn, reduces the bioavailable
NO in the form of reduced GSNO. Indeed, in GSNOR knockout mice display enhanced
levels of SNO-proteins while attenuating experimental allergen-induced airway
hyperreactivity (asthma) and myocardial infarction (heart attacks), at the cost of endotoxic
shock being more severe.69 GSNOR plays a role in regulating airway smooth muscle tone,
as well as receptors in lungs and heart.70 As well, they display increased angiogenesis,
altered homeostasis of G protein–coupled receptors and decreased vascular resistance; due
to the increase in SNO proteins.69 Single-nucleotide polymorphism in GSNOR have been
discovered to be are linked with the increase or decrease of childhood asthma, while adult
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asthma is due to an increase GSNOR of levels and activity in the fluid of the airway
lining.69 Beyond heart failure and asthma, GSNO has been linked to other diseases as well,
including

Crohn’s

disease,

IBS,

autoimmune

encephalomyelitis,

autoimmune

uveoretinitis, and more.69
2.2.3 Inhibitor’s of GSNOR
The regulatory processes GSNOR are currently under investigation, with inhibitors
in particular being highly sought after. Due to dysregulation of GSNOR and GSNO
depletion is associated with various disease conditions, being able to control activity of
GSNOR in vivo is of interest.71
Perhaps the most prolific advancement in GSNOR medicine, is the development of
Cavosonstat (N91115), a GSNOR inhibitor to aid cystic fibrosis patients with the ΔF508CFTR mutation. This is a mutation within the gene for the cystic fibrosis transmembrane
conductance regulator (CFTR), and is responsible for two thirds of cystic fibrosis cases
world wide.72 N91115 works to inhibit GSNOR so GSNO is available to promote CFTR
maturation and plasma membrane stability.73 With an increase in GSNOR activity and
expression, there is less GSNO available to propagate protein-SNO signaling. Increasing
the in vivo levels of S-nitrosothiol’s aids to modulate dilation of the airways, and the
proteins that work to degrade CFTR.73
The increase in NO bioavailability by inhibiting GSNOR benefits other disease
states as well. Vascular disorders in particular. N6022 is another inhibitor that made it to
clinical studies. As a tight-binding, specific, and reversible N6022 is a potent inhibitor that
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has applications with asthma, chronic obstructive pulmonary disease, and IBS.74 Another
inhibitor, N6338, has been found to reduce blood pressure and vascular resistance in
hypertensive rats.75 There are other novel inhibitors70,

74

that have been developed,

however, N91115 and N6022 have had the most success.
Recent research has also found GSNOR to be influenced by S-nitrosylation. One
2016 study found that the nitrosation of conserved cysteines downregulated the enzyme.65
A reactive oxygen species (ROS)-mediated inhibition of GSNOR has also be discovered.76
Peroxide treatments led to oxidative modifications on the structural zinc, decreasing the
rate of GSNO metabolism and contributing to the activation of anti-oxidative mechanisms.
2.2.4 Deviations & Classical Enzymatic Kinetics
The rates of reactions for enzymatic processes can be monitored and explained
through various kinetic parameters over the course of a reaction. A general reaction
scheme, Equation 2.2.4a describes a reversable joining of the enzyme (E) and the substrate
(S), to form an enzyme-substrate complex (ES), along with the forward (k1) and reverse
rates (k-1) of reaction. For the progress of the reaction to come to completion, the ES
complex performs its function in order to release the reaction product (P); this corresponds
to its own rate (k2).77

Equation 2.2.4a:
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The classical model to describe enzyme kinetics was described by and named after
Leonor Michaelis and Maud Menten. The Michaelis-Menten model describes the rate
equation for the process shown in Equation 2.2.4a as a function of substrate concentration.
The rate equation, Equation 2.2.4b, demands several assumptions for the fit to be a perfect
match for experimental data. This includes an assumption for instantaneous chemical
equilibrium during the formation of ES (k-1 >> k2), as well as the use of steady state
conditions ([S] >> [E]).77

Equation 2.2.4b: 𝒗𝒐 =

𝑽𝒎𝒂𝒙 [𝑺]
𝑲𝑴 + [𝑺]

=

𝒌𝒄𝒂𝒕 [𝑬]𝑻 [𝑺]
𝑲𝑴 + [𝑺]

Upon first glance of the Michaelis-Menten equation (Equation 2.2.4b), three
parameters present themselves, while others can be derived. The Michaelis constant (KM)
is derived from the combination of rates displayed in Equation 2.2.4a. This is shown in
Equation 2.2.4c, operationally KM corresponds to the concentration of substrate at half the
maximal velocity (Vmax). At the maximal velocity, [S] >> KM and the reaction velocity
equation can be represented by using k2[E] instead of Vmax, under these conditions, k2
represents kcat, the catalytic constant. This constant is then used to measure the catalytic
efficiency, or turnover number, of the system (Equation 2.2.4d).77-78 The catalytic constant
is defined in Equation 2.2.4e.

Equation 2.2.4c: 𝑲𝑴 =

𝒌−𝟏 + 𝒌𝟐
𝒌𝟏

Equation 2.2.4d: 𝑪𝒂𝒕𝒂𝒍𝒚𝒕𝒊𝒄 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 =

59

𝒌𝒄𝒂𝒕
𝑲𝑴

Equation 2.2.4e: 𝒌𝒄𝒂𝒕 =

𝑽𝒎𝒂𝒙
[𝑬]

Deviations from the Michaelis-Menten model require further consideration in order
to accurately represent the enzymatic system. Such is the case for allosteric enzymes. The
term allosteric describes enzymes that have integrations at a site other than the catalytic
site that influences activity.78 Allosteric modulators can include external ligands or the
substrate itself and can offer a variety of effects. Binding of a modulator can affect the
binding affinity of the substrate, affect the rates of the catalysis, or offer conformational
changes.78 When the binding at an allosteric site affects the binding to the active site, this
is called a cooperative process, which can proceed in a positive or negative manner. These
changes affect the steady-state kinetic trend, offering deviations from the MichaelisMenten curve. While non-allosteric enzymes form a rectangular hyperbolic curve,
cooperative binding results in sigmoidal curves depending on the degree of cooperativity.
A sigmoidal deviation in the O2 binding curve of haemoglobin was first described
by Archibald Hill.77 The resulting Hill Equation (Equation 2.2.4f) can be used to provide
a more accurate fit for cooperative steady state kinetic data. A couple of marked differences
differentiates the Hill Equation from the Michaelis-Menten curve, including the inclusion
of the Hill constant, n, and the renaming of KM to K0.5. The Hill constant, n, provides the
degree of cooperativity, when n=1 there is noncooperative behaviour and the curve is
identical to a Michaelis-Menten plot. With n<1 there is noncooperative allostery and n>1
corresponds to positive cooperativity with allosteric binding.

Equation 2.2.4f: 𝒗𝒐 =

𝑽𝒎𝒂𝒙 [𝑺]𝒏
𝒏
𝑲𝒏
𝟎.𝟓 + [𝑺]
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Deviations from Michaelis-Menten resulting in positive cooperativity is shown in
Figure 2.2.4a, while deviations resulting in various degrees of positive and negative
cooperativity is shown in Figure 2.2.4b. With a positive modulator (n>1), binding of the
modulator enhances further binding of the substrate, resulting in a large increase in reaction
velocity after K0.5, allowing the enzyme to reach Vmax faster. At low substrate
concentrations, below K0.5, the enzyme is in a less active confirmation, resulting in lower
reaction rates in comparison to a noncooperative enzyme adhering to similar parameters.
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Rxn Velocity

Vmax
Hill Plot (n=2)
Michaelis-Menten Plot

½ Vmax

K0.5 & KM

[S]

Figure 2.2.4a: Classical Michaelis-Menten curve in comparison to a Hill plot
displaying positive cooperativity. Constructed with identical Vmax and KM=K0.5. n=2 for

Rxn Velocity

the Hill plot, n=1 for the Michaelis-Menten curve.

Vmax

n=4
n=2
n=1
n=0.5
n=0.25

½ Vmax

K0.5

[S]

Figure 2.2.4b: Various sigmoidal Hill plots. Constructed using various hill coefficients
(n), and identical Vmax and K0.5 values. Positive cooperativity is shown in the green (n=4)
and purple (n=2) curves, noncooperatively in the red (n=1) curve and negative
cooperativity in the yellow (n=0.5), and blue (n=0.25) curves.
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2.2.5 Electrospray Ionisation Mass Spectrometry (ESI-MS)
Mass spectrometry (MS) allows for the analytical analysis of molecular ions. It is
an invaluable tool to identify, characterize, and quantify biomolecules.79 Electrospray
ionization (ESI) was adapted for tandem use with mass spectrometry in the 1960s, but it
was not until the mid 1980s when the technique was adapted for use with proteins and
peptides.80-82 Advancements in this field aided greatly in the advancements in proteomic
studies.79 The 2002 Nobel Prize in Chemistry was split by John Fenn, for his work on ESIMS.
There are several steps involved in obtaining ionized analyte. The liquid sample,
prepared in a volatile solvent, is fed through a metal capillary held at a high electric
potential (2-6 kV). This current can be positive (+, protonation) or negative (-,
deprotonation) depending on the ion mode of the mass spectrometer. In positive ion mode,
the analyte will acquire net positive charges. With application of the current, these
positively charged ions gather at the tip of the capillary, forming a sharp ‘Taylor’ cone.83
When electrostatic repulsion becomes stronger than the surface tension, charged droplets
leave the cone the direction of the counter-electrode.84 During the flight, solvent evaporates
the particles get smaller in size, leading to larger charge densities.82 A flow of nebulizing
gas (N2(g), as shown in Figure 2.2.5a) adds shear forces to the droplets, aiding in
disintegration.84-85 With this deformation and reduction in size, and the increase in
electrostatic repulsion, the particle reaches its upper Rayleigh stability limit, resulting in a
‘Rayleigh explosion’ where the larger ‘parent’ particle surface turns into a protrusion
wherein the particle gives off a jet of ‘daughter’ microdroplets.84 This process continues
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until only bare ions remain. It is bare ions of interest that are completely sorted by their
mass charge (m/z) ratios and detected by the spectrometer.
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Figure 2.2.5a: Electrospray ionization of liquid analyte. With a high electric potential
applied to the analyte capillary, the otherwise round meniscus forms a cone where charges
collect (in this case, positive charges, for the application of a positive potential). Analyte
is released as fine mist to enter the mass spectrometer. As charged droplets enter the
counter-electrode, flowing through pressure and potential gradients aids in stripping ions
of solvent and of each other, allowing only bare ions be detected.
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2.2.6 Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS)
Hydrogen/deuterium exchange (HDX) mass spectrometry (MS) is a technique that
has become key in investigating the structural dynamics of a protein structures. This is
significant knowledge, to supplement the information that static structures obtained from
crystal structures.86 As well this technique can offer insights to protein-protein complexes,
protein-ligand interaction, protein mutations, post-translational modifications, and monitor
conformational changes due to functional changes.87 The pharmaceutical industry, in
particular, benefits from HDX-MS, in regards to protein-drug interactions.87
The exchange reaction occurs when a deuterium source is introduced to a protein
solution. Labile protons will exchange with the solvent, including -OH, -NH, and -SH
hydrogens.86 However, since the hydrogens of amino acid side chains can exchange on a
sub-millisecond time scale, most studies are concerned with the slower exchange that can
be monitored on peptide backbone amides.86, 88 Of the backbone amides, exchange is faster
on fully solvent exposed amides that are not involved in hydrogen bonding.
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Figure 2.2.6a: Hydrogen/deuterium exchange (HDX) with parallel β-sheets. Solvent
exposed, non-hydrogen bonding amide hydrogens will readily exchange with introduced
deuterium. Atoms involved in the change are showed in blue.
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The exchange rate of any given amide is dependent on the rate constant of the
chemical exchange (kch), combined with the rates of open (kop) and closed (kcl) confirmation
transitions of the amide.86 kch is influenced by the flanking side changes, reaction
temperature, and deuterium ion concentration (pD). The mechanism detailing the opening
of a closed amide, the deuterium exchange, and the return to a closed confirmation is shown
in Equation 2.2.6a.86 The rate of overall exchange (kHDX) can then be described as a
combination of these rates, with three possibilities: (1) If the rate of H to D change (kch) is
much greater than the rate of the amide closing (kcl), (kch >> kcl), then Equation 2.2.6b is
the simplified rate equation. This implies that exchange occurs during the first opening
event.86 (2) If the rate of closure (kcl) is much greater than the rate of the exchange (kch),
(kch << kcl), then Equation 2.2.6c is the simplified rate equation. This situation is more
common under physiological conditions. (3) If the amide is permanently unprotected,
Equation 2.2.6d is the simplified rate equation.86

Equation 2.2.6a:
Equation 2.2.6b: 𝒌𝑯𝑫𝑿 = 𝒌𝒐𝒑

Equation 2.2.6c: 𝒌𝑯𝑫𝑿 =

𝒌𝒐𝒑
𝒌𝒄𝒍

𝒌𝒄𝒉

Equation 2.2.6d: 𝒌𝑯𝑫𝑿 ≈ 𝒌𝒄𝒉
The exchange reaction can be acid, base, or water catalyzed, with the acid catalyzed
mechanism predomination at pH’s below 2. At pH levels between 2.0-3.0, water catalysis
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is dominant, with acid and base mechanisms contributing equally.89 It is here where the
exchange rate (kch) is at its lowest, with values 10,000-fold lower at pH 2.5, compared to
pH 7.0.89-90
HDX-MS experiments are capable of investigating protein-substrate interactions.
One method of doing so includes utilizing microfluidic set ups in order to perform
consistent and reproducible experiments. An example of this is the time-resolved
electrospray (TRESI) microfluidics set up developed by Wilson and Konermann.91 In a
quench-flow experiment, the exchange reaction is initiated by the rapid mixing of reagent,
and concluded by mixing with a quenching reagent. The TRESI device contains a series of
capillaries with an adjustable reaction volume that allows for static time-points and kinetic
measurements. The basis of the set up includes a larger metal capillary with a smaller glass
capillary inside. When the ends of the two are flush, the reaction volume is zero. When the
glass capillary is pulled deeper into the metal capillary, the reagents being pumped through
the two capillaries are allowed to mix. Protein solution flowing through the glass capillary
is mixed with deuterium oxide flowing around the glass, contained by the metal capillary.
The mixing volume, adjustable by the movement of the glass capillary, ends at a Tjunction, in which the solution is mixed with an opposite flow of quenching solution (acid).
The quenched reaction exits out the perpendicular channel, towards the ionization source
(ESI).
In this study, the enzyme S-nitrosoglutathione reductase (GSNOR) is characterized
computational studies, kinetic studies, and hydrogen deuterium exchange mass
spectrometry. These studies may support the existence of a possible allosteric site on the
69

enzyme. Further information on the HDX experiments performed here, as well as the use
and set up of the TRESI device is elaborated on in the Methods section of this chapter, in
Section 2.3.8, and Figure 2.3.8a in particular.
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2.3 Methods
2.3.1 GSNOR WT Cloning, Mutagenesis, and Protein Isolation
The original cloning and mutagenesis of the human ADH5 gene was performed by
Dr. Bei Sun. The final result was recombinant GSNOR containing two 6X-histidine tags,
one at each terminus, to aid in purification. The pET28b_ADH5 plasmid was then
transformed into BL21(DE3) E. coli for further work. Further detail on Dr. Sun’s work in
this regard can be found in Appendix A.
To begin protein isolation, a single pET28b_ADH5 in BL21 cellular colony was
picked from LB-kanamycin agar plates and grown in a sterile round bottom polypropylene
culture tube containing 4 mL of 2X YT media and 50 μg/mL kanamycin (YT kan); this
was left to incubate overnight at 37⁰C with shaking. This colony of cells was added to a
starter culture flask at a rate of 1 mL of colony per 100 mL of YT kan media; this was
grown for 8 hours at 37⁰C with shaking. This starter culture was used to inoculate 1 L of
YT kan media in a 4 L flask, at the same rate of 1 mL per 100 mL of media. This was then
left to grow overnight, shaking at room temperature. The next morning, GSNOR
expression was induced by the addition of IPTG to a final concentration of 0.4 mM. This
induced culture was left to incubate for 24 hours, shaking, at room temperature. The cells
were then harvested by centrifugation, the cells and their media were placed in 500 mL
Nalgene centrifuge bottles and centrifuged at 6,000 rpm for 30 minutes at 4⁰C. The
supernatant was subsequently discarded and the bacterial cell pellet was resuspended in pH
8 lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM PMSF, 1% Triton X-100, 75 μg/mL
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DNase I and 100 μg/mL lysozyme). The crude lysate was incubated on ice for 30 minutes
and further lysed by pulse sonication. This was done on ice, with 30 seconds on, 30 seconds
off, for a total of 8 pulses. The lysate was then centrifuged in 50 mL Nalgene centrifuge
bottles at 12,000 rpm for 30 minutes at 4⁰C. Further purification of the supernatant was
done using HIS-Select Nickle Affinity Gel (Sigma-Aldrich P6611).
The Ni affinity column, stored in 20% (v/v) ethanol, was equilibrated with wash
buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8) and placed in a 50 mL conical tube. The
lysate supernatant was added to the column matrix and allowed to mix for 1 hour at 4⁰C.
The lysate and matrix were returned to the glass chromatography column (Rio-Rad EconoColumn). The column matrix was washed with wash buffer, followed by 10 mM imidazole
wash buffer, and then 25 mM imidazole wash buffer before elution. Bound GSNOR was
then eluted with elution buffer (300 mM imidazole, 50 mM Tris-HCl, 150 mM NaCl, pH
8). The eluted protein was then buffer exchanged into storage solution (58 mM Na2HPO4,
17 mM NaH2PO4, 68 mM NaCl, 15% glycerol, pH 7.4) using 15 mL capacity Amicon
centrifugal filter tubes (Millipore Sigma UFC903008) and stored at -80°C.
2.3.2 GSNO Synthesis
The majority of the GSNO used for this project was synthesized by Leslie
Ventimiglia and Mark Potter.
GSNO was synthesized in-house as per previously determined protocols.92
Glutathione (GSH) was mixed in a 1:1 stoichiometric ratio of sodium nitrite (NaNO2) at
4⁰C in 0.5M HCl. After 40 minutes, acetone was added in 1:1 (v/v) and mixed for 10
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minutes until the red GSNO precipitated out of solution. The precipitate was subsequently
filtered and washed 3x with cold water, 3x acetone, and 3x ether. The GSNO was then
lyophilized and stored at -20⁰C. The concentration of any GSNO solution prepared out of
the lyophilized powder was confirmed by UV-Vis spectroscopy; as outlined in Section
2.3.3.

Figure 2.3.2a: Synthesis of GSNO.
2.3.3 GSNOR WT Kinetics & Kinetic Parameters
Steady state kinetic assays were performed using GSNO as a variable substrate, and
keeping cofactor NADH constant. 20 mM NADH stock solution was prepared with MilliQ (Advantage A10 Water Purification System, Millipore Sigma). GSNO stock solutions
were prepared fresh from lyophilized powder and pH 7.4 PBS into 10 mM and 1 mM stock
solutions. The true concentration of GSNO was obtained by measuring the absorbance of
the 1 mM solution at 335 nm, utilizing the molar extinction coefficient of 922 M-1 cm-1,
and Beer’s Law.93
GSNO, of increasing concentrations was added to a 500 μL cuvette containing 80
μM NADH and pH 7.4 PBS to a final volume of 500 μL. The kinetic reaction was initiated
by the addition of 2 μg of GSNOR. The concentration of stock GSNO was confirmed by
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Bradford Assay immediately prior to the experiment. The uptake of NADH during the
reaction was monitored by its decrease in absorbance at 340 nm, 60 seconds of reaction
was monitored by the Agilent 8453 UV/Vis spectrophotometer. The rate of the initial linear
decrease corresponding to NADH uptake was plotted in correlation to the concentration of
GSNO. From this, K0.5 and Vmax were calculated. Catalytic efficiency and kcat were
determined utilizing Equations 2.2.4d-e, respectively.
The experimental kinetic data was manipulated and plotted as per Equation 2.3.3ab to determine the Hill constant. The constant, n, was found as the slope of the resulting
line of best fit. This is due to the fact that the manipulation performed results in a graph
displaying Equation 2.3.3c, where K represents binding constants of the ligand.
Equation 2.3.3a: 𝒙 − 𝒗𝒂𝒍𝒖𝒆𝒔 = 𝐥𝐨𝐠(𝑿) = 𝐥𝐨𝐠([𝑮𝑺𝑵𝑶])

𝒀

Equation 2.3.3b: 𝒚 − 𝒗𝒂𝒍𝒖𝒆𝒔 = 𝐥𝐨𝐠 (𝟏−𝒀) = 𝐥𝐨𝐠 (

𝒚
𝑽𝒎𝒂𝒙
𝒚
𝟏−
𝑽𝒎𝒂𝒙

)

𝒀

Equation 2.3.3c: 𝒍𝒐𝒈 (𝟏−𝒀) = 𝒏 𝐥𝐨𝐠(𝑿) + 𝐥𝐨𝐠(𝑲)
2.3.4 Mass Spectrometry (MS)
All mass spectrometry was performed at York University in Toronto, Ontario in
collaboration with Dr. Derek J. Wilson and his Lab Manager Cristina Lento. All
experiments were performed by the author on a Waters Synapt G1 High Definition Mass
Spectrometer (Synapt G1) with an electrospray ionization (ESI-MS), schematic shown in
Figure 2.3.4a. The Synapt G1 utilizes Waters’ Triwave™ technology to allow for ion
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mobility separation (IMS); adding the separation based on mass and size to a given data
set. With the IMS function turned on, unresolved, overlapping, peaks can be separated and
analyzed. Analyte enters the mass spectrometer through electrospray ionization (ESI). Ion
obtain a net positive charge through the application of a positive potential electric field.
The formation of charged droplets results in solvent evaporation and gas-phase ions of
interest. Electrostatic attraction and a vacuum allow the ions to enter into the spectrometer.
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LOCKMASS
REFERANCE SPRAY
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ANALYTE SPRAY

OIL-FREE
SCROLL PUMP

AIR-COOLED TURBOMOLECULAR PUMPS

Figure 2.3.4a: Waters Synapt G1 Definition Mass Spectrometer schematic. Analyte is
ionized from an electrospray source and incoming ions are focused by the T-wave ion guide
mass ion selection by the quadrupole. The Triwave™ technology works with three ‘waves’
that perform three distinct functions: the first wave traps and releases ions, the second
separates ions by their ion mobility and the final wave transfers ions to the time of flight
(TOF) mass analyzer. Further fragmentation by collision induced dissociation (CID) can
be performed before or after ion mobility separation.
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2.3.5 GSNOR WT Native MS
Purified recombinant GSNOR was dethawed and storage buffer was buffer
exchanged with 200 mM ammonium acetate, using a 15 mL compacity Amicon centrifugal
filter tube. Protein was injected into the Synapt G1 mass spectrometer at a rate of 6 μL/min
and data was recorded in positive ion mode at a range of 500-8000 m/z. Other system
settings are overviewed in Table 2.3.5. The electrospray voltage settings are consistent for
all MS data sets.
Table 2.3.5: Native GSNOR Synapt G1 Operating Settings.
Electrospray Ion Source Voltage Settings
Capillary Voltage

3.00 kV

Sampling Cone

50 V

Extraction Cone

2.0 V

Operating Pressures (Torr)
Trap

1.06 x 10-2

IMS Cell

5.22 x 10-4

TOF

7.63 x 10-7

Backing Pressure
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2.22

2.3.6 GSNOR WT Peptide Fragmentation
MS1 fragmentation of native GSNOR WT is done using pepsin agarose beads
placed in a fabricated poly(methyl methacrylate) (PMMA) chip that allows for lowpressure proteolysis with on-chip ESI. Fabricated as previously described by Wilson and
colleagues.94 The PMMA chip is shown in Figure 2.3.6a (i) while the assembled
microfluidics apparatus is shown in Figure 2.3.6a (ii); this set up includes the bluecoloured pepsin agarose beads, the entrance connector carrying native protein, ready for
proteolysis, and an exit channel, towards ionization by electrospray and analysis by the
Synapt G1 MS. The stock aliquots of pepsin agarose beads used are maintained by the
Wilson Lab.
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(i)

(ii)
Native Protein Solution

Microfluidics Chip

Pepsin Agarose Beads

Peptides to MS

Positive Electric
Potential (3 kV)

Figure 2.3.6a: PMMA chip for protein proteolysis.
(i) PMMA chip, with entrance channel and an exit channel, connected by the
proteolysis reaction chamber.
(ii) Native protein solution is pumped into the PMMA microfluidics chip containing
pepsin agarose beads for low-pressure proteolysis. The peptides then exit the pepsin
resin for ESI to enter the Synapt G1 spectrometer.
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2.3.7 GSNOR WT MS-MS for Peptide Identification
Tandem mass spectrometry (MS-MS, or MS2) is utilized for characterization of the
peptides fragmented from the pepsin column. By acquiring data in MS-TOF mode, a
precursor ion can be chosen to undergo further fragmentation by CID. The collision energy
applied was customized for each precursor ion to obtain an ideal fragmentation pattern.
The fingerprint spectra were collected within a mass range of 100-2000 m/z.
A theoretical pepsin digest was performed using FindPept tool on the ExPASy
Proteomics server (Swiss Institute of Bioinformatics, Basel). Search parameters were set
to pepsin (porcine A) at pH > 2 with a mass tolerance of ± 0.5 Da. The possible identities
of the parent ion were chosen from the resulting list. Each possible parent ion was
theoretically fragmented by the spectra viewing software mMass and compared with the
fingerprint. The parameters used included searching for the loss of -H2O and -NH3, as well
as identifying y, a, b, int-a, and int-b fragment ions.
2.3.8 GSNOR WT HDX-MS
Hydrogen deuterium exchange (HDX) MS was made possible by outfitting the
Synapt G1 with the custom TRESI apparatus as described by Wilson et al.91 The reagents
utilized include 5% (v/v) acetic acid, GSNOR in 200 mM ammonium acetate, and
deuterium oxide (D2O) (99.9% purity of LC-MS grade, Sigma-Aldrich). These reagents
are pumped through polyamide-coated glass capillary with an outer diameter (o.d.) of 109.2
μm using Harvard Apparatus Pump 11 Elite infusion syringe pumps (Holliston, MA).
Protein and D2O were pumped at a rate of 2 μL/min with 0.5 mL syringes (Hamilton 700
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Series Gastight Syringe) while acid was pumped at a rate of 16 μL/min with a 5 mL or 2.5
mL syringe (Hamilton 1000 Series Gastight Syringe).
The TRESI microfluidics apparatus describes where the mixing of protein and D2O
takes place. The 109.2 μm o.d. glass capillary containing protein is encased in a metal
capillary with an inner diameter (i.d.) of 132.6 µm. A 2 mm notch was made and the end
of the glass capillary was sealed, this allowed for efficient kinetic mixing before the
exchange reaction was quenched by the acid and sent to the PMMA chip containing the
pepsin agarose beads for MS1 fragmentation. The creation of the notch and the melting the
end of the glass capillary was done fresh for each experiment using a VersaLaser™ as
described.91 Measuring different time points of D2O incorporation is done by measuring
the distance allowed from the end of the ‘plug’ (Figure 2.3.8a (i)) to the end of the outer
capillary. The schematic of this device and its physical manifestation is shown in Figure
2.3.8a.
The HDX-MS experiments conducted for this report utilized 5 mm and 10 mm
reaction spaces, which corresponds to 2.07 seconds (~2 secs) and 3.93 seconds (~4 secs),
respectively. Data was collected in IMS mode in the 400-1500 m/z range. The operational
settings and average operational pressures for these experiments are summarized in Table
2.3.8. The experimental deuterium uptake of each peptide obtained was calculated using a
custom-built software program (DJW, unpublished results).
Each set of data was collected on the same day, including three 5 min spectra
acquisitions of: protein GSNOR without deuterium exchange, two secs exchange, and four
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secs exchange. Followed by three 5 min spectra acquisitions of: protein GSNOR + 20x
excess of GSNO without deuterium exchange, two secs exchange, and four secs exchange.
Concentrations of GSNOR and GSNO were calculated by Bradford assay and UV-Vis,
respectively, to confirm a 20x stoichiometric addition of GSNO. Integrity of the notch was
confirmed to be maintained at the end of the experiment.
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(i)

(ii)

Protein

Acid

D2O

Figure 2.3.8a: TRESI microfluidics set up for HDX-MS.
(i) Schematic for D2O and protein mixing, followed by acid quenching and
fragmentation by pepsin. Protein solution exits the notch and immediately mixes
with D2O, the space from the end of the glass inner capillary to the end of the metal
outer capillary corresponds to the exchange reaction time.
(ii) Complete set up of the TRESI device connected to the PMMA chip.
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Table 2.3.8: HDX-MS GSNOR Synapt G1 Operating Settings.
Electrospray Ion Source Voltage Settings
Capillary Voltage

3.00 kV

Sampling Cone

50 V

Extraction Cone

1.5 V

Operating Pressures (Torr)
Trap

2.19 ± 0.15 x 10-2

IMS Cell

5.66 ± 0.37 x 10-1

TOF

7.99 ± 0.22 x 10-7

Backing Pressure
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2.17 ± 0.05

2.4 Results
Sigmoidal deviations resulting in positive cooperativity were identified with
GSNOR kinetics. To further investigate the allosteric effect, molecular docking (MD)
simulations were performed to look for a possible allosteric binding site for substrate
GSNO. Electrospray mass spectrometry (ESI-MS) was also utilized it identify proteinligand interactions. The MS experiments performed here include: native MS for dimer
identification, MS-MS for peptide identification, and hydrogen–deuterium exchange
experiments (HDX-MS) for the investigation of direct ligand interactions.
2.4.1 GSNOR WT Kinetics
Steady state kinetic assays of recombinant wild type GSNOR were performed in
triplicate, with one set of representative data being displayed throughout this section. Upon
assessment of the kinetic parameters of GSNOR, the apparent KM, or K0.5, was 16.7 ± 0.53
μM towards GSNO with a kcat of 120000 ± 40000 s-1. The catalytic efficiency, calculated
as kcat/K0.5, was found to be 12000 ± 2000 s-1 M-1. These values, as well as the Hill constant
(n), are summarized in Table 2.4.1.
To determine possible allostery, the Hill coefficient was deduced to quantitatively
determine the cooperativity of ligand binding. The kinetic data for reactions containing 070 μM GSNO were used to construct a Hill plot, as shown in Figure 2.4.1a. The resulting
Hill constant observed was 1.49 ± 0.037.
With the Hill constant calculated, fit curves can be applied to the experimental data,
as in Figure 2.4.1b (i-ii). The featured data is shown with the classical Michaelis-Menten
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curve (n = 1) as well as the corresponding Hill plot (n = 1.54). Figure 2.4.1b (ii) offers a
closer look at the lower concentrations.
Table 2.4.1: GSNOR WT Kinetic Parameters.
Kinetic Parameter

Value

K0.5 (μM) (n=3)

16.7 ± 0.53

kcat (x105 s-1) (n=3)

1.2 ± 0.4

kcat/K0.5 (x104 s-1 M-1) (n=3)

1.2 ± 0.2

n (n=3)

1.49 ± 0.037
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Figure 2.4.1a: Hill plot for the discovery of the Hill constant (n). Utilizing
representative data of 0-60 μM GSNO, the Hill constant is determined by the slope of the
line of best fit, n = 1.54.
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Figure 2.4.1b: Representative GSNOR WT kinetic data. Initial reaction rates measured
by monitoring the decrease in absorbance at 340 nm. Each reaction contained 80 μM of
NADH and was initiated by the addition of 2 μg of enzyme. Error bars represent standard
deviation (n=3). Displayed is a Michaelis-Menten fit curve (K0.5 = 16.8 μM, n = 1, blue
dashed curve) contrasted with a Hill plot (K0.5 = 16.8 μM, n = 1.54, solid red curve).
(i) Substrate range: 0-200 μM GSNO.
(ii) Substrate range: 0-60 μM GSNO.
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2.4.2 Native GSNOR WT MS
Obtaining the mass spectra for the native protein GSNOR allows for calculation of
the molecular weight. As well as viewing monomers, dimers, trimers, etc., if applicable.
Performing this experiment proves that the dimer is involved in the HDX experiments,
however not the protein solution is not purely dimerized.
The spectra obtained can be found in the Appendix Figure B.1, with peaks
corresponding to monomeric GSNOR and dimerized GSNOR. The m/z values for these
peaks is summarized in Appendix Table B.1. While the monomer peaks display as broad
and unresolved, each subsequent dimer peak appears as three relatively distinct peaks
(termed 1st, 2nd, and 3rd from low to high m/z). The molecular weight of these peaks were
determined using ESIprot Online.95 The results are displayed in Table 2.4.2. The three
dimer peaks have an average first difference of 635 Da. Since GSNOR is known to carry
NADH molecules throughout the purification process, this stepwise increase in mass could
be explained by a dimer set with no NADH, a dimer with one monomer containing NADH,
and a dimer with both monomers containing NADH. The molecular weight of NADH is
663 g/mol, which is within the combined errors of each calculated MW.
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Table 2.4.2: Experimental MW of GSNOR, derived from native MS.
Molecular Weight (Da)
Monomer

43384.06 ± 29.17

1st Dimer

86285.54 ± 54.54

2nd Dimer

86944.87 ± 47.89

3rd Dimer

87554.32 ± 29.43
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2.4.3 GSNOR WT MS-MS Coverage Map
Obtaining identification of each peak in in MS fingerprint is necessary in order to
produce a heat map of deuterium uptake. Thirty-two MS-MS spectra were obtained and
successfully matched to peptide fragments of GNSOR. These peptides identified 188
unique amino acids which corresponds to about 50% sequence coverage. The list of these
peptides and the corresponding sequence map is displayed in Appendix B. The sequence
coverage can be extended by successfully matching other MS-MS spectra with the proper
peptides. As well, incorporating chromatography in the MS process could theoretically
help to increase the resolution of the peptides and aid in MS-MS data collection.
2.4.4 Previous Computational Studies
Previous molecular dynamics (MD) simulations were conducted in collaboration
by Dr. B. Sun and Dr. B Mutus with Dr. James Gauld and his student S. Nikoo. These
studies were performed in order to provide speculation into the possible allosteric binding
site of GSNO.
A template crystal structure (PDB ID: 3QJ5) was used to perform the docking
simulations using Molecular Operating Environment software (MOE, 2013.08; Chemical
Computing Group Inc. Montréal, QC, Canada).96 The results of the model implicated four
amino acids in the binding of GSNO at a putative allosteric site. Asn185 and Gly321
appeared to interact with GSNO directly while Lys188 and Lys323 interacts indirectly,
through a solvent network of hydrogen bonds. The study also provided docking score; these
are used to predict binding affinity, with a low score indicating stability and favorable
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interactions. GSNO binding at the active site gave a score of -8.60 while the putative
allosteric site has a score of -10.4.96
This punitive allosteric binding of GSNO and the implicated amino acid residues
are displayed in Figure 2.4.4a.
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Gly321
Lys323

Putative allosteric
GSNO Binding Site

Structural
Zinc

Asn185
Lys188

Catalytic
Zinc

NADH

Figure 2.4.4a: Putative allosteric site near the structural zinc, as discovered by MD
simulations. Asn185 and Gly321 are predicated to interact with GSNO directly while
Lys188 and Lys323 interacts indirectly.
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2.4.5 GSNOR WT HDX-MS
The custom TRESI device allowed for two static time points for the deuterium
exchange reaction to occur; two seconds and four seconds were chosen.
Of the data obtained, six sets of data describing GSNOR peptides as they respond
to deuterium incorporation were successfully analyzed. Sample spectra of this data can be
seen in Appendix D, in Figures D.1-3. Baseline spectra displays peptides in a typical
fashion of ESI peptides (Figure D.1); with the with the highest intensity peak being the
first peak and subsequently decreasing in intensity. As deuterium is incorporated (Figure
D.2-3), the peak distribution shifts with the addition of the heavier isotope. This shift is
used to observe the overall amount of deuterium that is taken up by the peptide. The next
layer of data incudes the incorporation of the substrate GSNO. Sample spectra of GSNOR
+ GNSO data can be seen in Appendix D, in Figures D.4-6. Two sets of GSNOR + GNSO
HDX data were successfully analyzed.
Twenty times the concentration of GSNO was mixed in GSNOR, to ensure
sufficient substrate was available to be observed interacting with the active site, as well as
the putative allosteric site. While there are some subtle changes that can be viewed between
the two spectrums’, the most obvious is the appearance of a 613 m/z (z = 1) peak after the
addition of GSNO. Based off literature MS studies of the GSNOR’s kinetic processes, it is
most likely that this peak corresponds to GSSG.67 This is not unexpected, since the GSNO
synthesized in-house was not completely pure, and degrades over time. This would lead to
GSH being present in the sample used, and is also why the concentration if GSNO used is
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always confirmed with UV-Vis spectroscopy on the day of use. As well, it is not possible
to purify GSNOR without residual NADH carried throughout the process. With the
substrate and the cofactor present, some GSNO would be metabolized by the enzyme,
leading to GSSG since GSH is present (Figure 2.2.2a). Excess GSNO and GSOOH (if any
was produced) was not witnessed since both molecular weights are below 400 Da, and thus
below the threshold of data acquired.
The results of these HDX-MS experiments are summarized in Appendix D. Table
D.1 offers a closer look at the peptide (I)PLYIPQCG(E) (residues 91-98). Here, the visible
change that deuterium incorporation has on the peptide’s peak distribution can be seen.
Numeric summary of the two second exchange reaction time is displayed in Table D.2 and
the four second exchange reaction is in Table D.3. These tables provide the baseline
deuterium uptake (%) for each peptide, which represents GSNOR data without GSNO. As
well as the deuterium uptake (%) for each peptide with GSNO incorporated. The values of
consequence, however, is the difference between these two values. Those values are what
is superimposed on the crystal structures (Figures 2.4.5 (a-b)) to pictorially view the
response to the presence of GSNO.
Four amino acid residues were implicated by computational means as being
involved in the interaction of GSNO at a putative allosteric site; Asn185, Gly321, Lys188,
and Lys323 (Figure 2.4.4a). While Asn185 is not represented by the identified peptide list,
Lys188 and Lys323 are, as well as Gly321, which is represented twice. Under a two second
exchange reaction, these residues all show a decrease in deuterium uptake (Table 2.4.5).
This is displayed in Figure 2.4.5a, where the decrease in uptake is denoted with increasing
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shades of red. Areas with the largest decrease in uptake can be seen around this putative
site, as well as in the active site pocket.
The results of the two second exchange reaction is at a contrast with the four second
exchange. With double the time for allowed mixing, the majority of peptides displayed an
increase in deuterium uptake. The notable exceptions are some peptides around the NADH
binding region, as well the peripheral peptides in the same area. These peptides, located in
the lower right quadrant of Figure 2.4.5 (a-b) show remarkedly similar uptake patterns at
both time points. This exception also includes Lys188, whose peptide displays an uptake
difference that is more negative than compared to the two second exchange data (Table
2.4.5).
Table 2.4.5: Δ Deuterium uptake of the amino acid residues implicated in allosteric
biding.

2 sec Exchange
Δ Deuterium
Uptake (%)

4 sec Exchange
Δ Deuterium
Uptake (%)

Representing
Peptide Sequence

N/A

N/A

N/A

-0.9

+0.1

(W)/KGTAFGGWKS(V)

-1.4

+0.5

(F)/GGWKSVESVPK(L)

Lys188

-0.4

-0.6

(T)AKLEPGSVC(A)

Lys323

-1.4

+0.5

(F)/GGWKSVESVPK(L)

Asn185
Gly321
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Figure 2.4.5a: HDX-MS heat map after two seconds of deuterium exchange. Red
conveys a decrease in deuterium incorporation after in inclusion of GSNO, Blue conveys
an increase. The putative allosteric binding site with GSNO is shown, along with labels of
the implicated resides involved in allosteric binding.
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Figure 2.4.5b: HDX-MS heat map after four seconds of deuterium exchange. Red
conveys a decrease in deuterium incorporation after in inclusion of GSNO, Blue conveys
an increase. The putative allosteric binding site with GSNO is shown, along with labels of
the implicated resides involved in allosteric binding.
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2.5 Discussion
In addition to the preliminary computational studies, the enzyme kinetics of
GSNOR, and HDX-MS studies at two reaction time points have been analyzed in the effort
of supporting the hypothesis of the existence of an allosteric site.
2.5.1 GSNOR Kinetics
The steady state kinetic assays performed provide a convincing basis for the
hypothesis of allosteric binding. With a Hill number (n) of 1.49 ± 0.037, there is indication
of some form of cooperative binding being observed. In addition to this, the Hill Plot curve
has a far superior fit in comparison to the basic Michaelis-Menten curve (Figure 2.4.1b);
while utilizing the same values for Vmax and K0.5/KM, which were experimentally derived.
The Hill Plot can account for the slower rates when approaching K0.5 while also observing
the faster ascent to Vmax that positive allosteric binding makes possible.
2.5.2 GSNOR HDX-MS: Two Second Exchange
Of the residues implicated in allosteric binding, Gly321, Lys188, and Lys323 have
representing peptides identified by MS-MS. As can be seen in Figure 2.4.5a, these
residues, and other peptides surrounding the computational placement of GSNO exhibit a
decrease in deuterium uptake. Gly321, which is represented twice, displays a decrease of
0.9% and 1.4%, while Lys188 shows on a peptide that decreased of 0.4% and Lys323
decreased of 1.4%.
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A decrease in deuterium uptake in peptides leading to the active site pocket,
peptides involved in binding NADH, and of those binding to the catalytic zinc, was also
observed. This included the amino acid residues Cys45 (-0.4%, TAVCHTDAYTLSGAD),
His67 (-0.3%, ILGHEGAGIVESVGEG; -0.7%, GHEGAGIVESVGEGVT), and Glu68 (0.3%, ILGHEGAGIVESVGEG; -0.7%, GHEGAGIVESVGEGVT), of which are involved
in the binding of the catalytic zinc. Observing this decrease in solvent exposure around the
active site is not unexpected or unwelcome; the fact that GSNO causes a change here adds
another layer of legitimacy to the observations at the putative site. Further speculation on
the HDX-MS structure patters can be found in Section 2.5.3.
The conformation of the structure used to display this data was obtained as a
computationally minimized structure, followed by an induced fit at the active site.96 The
consequence of this is that the static image shows the monomer as slightly puckered, in
comparison to the dimerized crystal structure (PDB ID: 3QJ5). Since Lys188 is the residue
that displayed a decrease in solvent exposure at both time points, the distance between the
α-carbon of Lys188 and the structural zinc since was chosen to display the differences in
confirmation after binding of GSNO. The physical location of the other amino acid residues
implicated in binding are located between Lys188 and the structural zinc. In the
computationally untouched dimerized crystal structure, the distances displayed are 24.4 Å
and 23.2 Å. The monomeric structures of the MD simulations have a shorter distance of
22.0 Å. Computationally minimized structures of the enzyme with GSNO in the allosteric
site and active site, as well as just at the active site, while being bound as a dimer would be
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of interest; the further explore the structural effects of the allosteric site. Figure 2.5.3a (iiiiv) depict these distances.
Table 2.5.2: Distance between Lys188 and the structural zinc. These distances were
determined using UCSF Chimera software.
Structure:

Distance between Lys188 and structural
zinc (Å):

Dimerized crystal structure

24.409, 23.150

Minimized monomer

22.014

2.5.3 GSNOR HDX-MS: Four Second Exchange
With double the reaction time, the data obtained from the four second reactions
move to more extreme changes in the uptake levels. While the two second reactions gave
peptide changes in the -1.8% to +3.4% range, the four second reactions were found to be
between -5.2% to +5.1% deuterium uptake change. As well, the majority of the peptides
presented an increase in uptake levels, with only five peptides in the negative range. To
counter this, there are also larger standard deviations in the values obtained for each
peptide; the most extreme peptides on either side both have errors around 4%, easily the
highest of all the data presented. This is not to negate the obvious trend observed, since
there is clearly an increase in deuterium uptake across the span of peptides. With a longer
time for the exchange reaction to occur, more time is present for the D2O to displace the
ligand-containing solvent surrounding the enzyme. The consequence of this larger time is
that any observations of ligand interactions is essentially exchanged away. All that can be
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said for the amino acid Gly321 and Lys323 is that they do not exceed +0.5% change in
deuterium uptake, while Lys188 exhibits -0.6% uptake.
The GSNOR dimer arranges itself with a central axis of β-pleated sheets. The
regions that continue to display a decrease in deuterium uptake (with similar patterns to the
two sec exchange data) are placed at each end of this ‘column’ of β-sheets. In the dimerized
image shown in Figure 2.5.3a (i-ii). One explanation for retention of negative uptake is
that this section of the protein is less flexible, with more hydrogen bonding, and less likely
to be affected by the increase in reaction time. It is entirely possible that this is the real
putative site for GSNO docking, however, it is unlikely that GSNO would display a
stronger interaction here over the active site.
The dimerized image in Figure 2.5.3a (iii) offers another perspective of the
allosteric region; the dimers has been rotated 180⁰ on a horizontal axis, offering a ‘backside’ view in comparison to the Figure 2.5.3a (i-ii) orientation. Although the GSNO is not
shown, the binding regions of the allosteric site are shown by blue ovals. The blue dashed
line connects Lys188 to the structural zinc.
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(i)

(ii)

Figure 2.5.3a (i-ii): HDX-MS heat maps with dimerized GSNOR.
(i) GSNOR two second reaction data on dimerized structure.
(ii) GSNOR four second reaction data on dimerized structure.
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(iii)

(iv)

Figure 2.5.3a (iii-iv): HDX-MS heat maps with dimerized GSNOR.
(iii)‘Back-side’ view of four second reaction data; 180⁰ horizontal rotation of (ii). Blue
circles demonstrate location of allosteric GSNO binding. Blue dashed lines denote
the distance between the α-carbon of Lys188 and the structural zinc. The distances
are 24.4 Å for the left sided monomer and 23.2 Å for the right.
(iv) Similar orientation of (iii), of the four second reaction data. GSNO is shown; blue
dashed lines denote the distance between the α-carbon of Lys188 and the structural
zinc, 22.0 Å.
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2.6 Conclusion
This chapter supports the existence of a possible allosteric site on the enzyme Snitrosoglutathione reductase (GSNOR). Experimental kinetic data provided a sigmoidal
curve with a Hill coefficient (n) of 1.49 ± 0.037. This being greater than 1 suggests that the
substrate S-nitrosoglutathione (GSNO) is binding in a cooperative manner. Molecular
docking simulation on monomeric GSNOR presented a GSNOR binding site, located near
the structural zinc. The amino acid residues Gly321, Lys323, Asn185, and Lys188 were
implicated in the binding of GSNO at this site; peptides containing Gly321, Lys323, and
Lys188 were successfully characterized by MS-MS. TRESI-HDX-MS studies were
utilized to investigate this site further. Two and four second hydrogen to deuterium
exchange reaction time points were observed. Under a two second HDX, the residues
Gly321, Lys323, and Lys188 displayed a decrease of 1.4%, 1.4%, and 0.4%, respectively,
after the addition of GSNO to the enzyme solution. This corresponds to a decrease in
solvent exposure on the enzyme and supports the computational docking studies. Decreases
were also observed around the active site, and NADH binding region. Under a four second
HDX, the vast majority of peptides displayed an overall increase in deuterium uptake, in
solvent exposure. This includes active site peptides and eludes to four seconds being too
long to observe the interactions of GSNOR and GSNO.
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2.7 Future Directions
To further investigate the validity of the putative allosteric site, site directed
mutagenesis on Lys323 and Lys188 is in progress. By mutating both Lys323 and Lys188
to alanine, the loss of allosteric effects is hypothesized to be lost in the kinetic data. Other
work includes successfully obtaining a third set of HDX-MS data of GNSOR + GSNO. As
is, four sets of data were collected, with two sets being discarded due to discrepancies
within the HDX GSNOR + GNSO spectra. One set was discarded due to notch failure of
the TRESI device and thus improper mixing, leading to a dramatically reduced deuterium
uptake observed. The second set of data discarded resulted in similar patterns, with very
little deuterium uptake after the addition of GSNO despite the experimental conditions; the
reasons for this has yet to be deduced. A third set is needed to have a complete triplicate
data set.
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APPENDIX A – Recombinant GSNOR
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Figure A.1: Recombinant wild type GSNOR protein sequence. Amino acids are
numbered from Met1 to Ile374, excluding the added histidine-tag (italicized).
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Figure A.2: Recombinant GSNOR Plasmid Map.
The following was designed and performed by Dr Bei Sun.96
Human ADH5 was purchased from Origene (SC119755) and sub-cloned into the
bacterial expression vector pET28b using Cold Fusion Cloning Kit (MJS BioLynx Inc.
SYMC010A1). The following primers for PCR were designed according to manufacturer’s
guidelines:
Forward 5’ –GTGCCGCGCGGCAGCCATATGGCGAACGAGGTTATCAAG– 3’
Reverse 5’ –GTGGTGGTGGTGGTGCTCGAGAATCTTTACAACAGTTCGAATG– 3’
Colonies were screened using diagnostic restriction enzyme digest and by partial
sequencing (Robart’s Research Institute, London Regional Genomics Center, London,
Ontario, Canada). The final recombinant GSNOR contains a 6X-histidine tag at each
terminus.
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Figure B.1: Native GSNOR MS Spectra. Peaks shown in the 3000-6000 m/z window.

Three broad monomer peaks followed by dimerized GSNOR.
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APPENDIX B – Mass Spectrometry: Native GSNOR

Figure B.1 continued,
(1) – (3) Tertiary (3⁰) GSNOR, corresponding to monomer detection.
(4) – (7) Quaternary (4⁰) GSNOR, corresponding to dimerized GSNOR.
Table B1: Native GSNOR MS spectra peak m/z values and relative intensities.
Figure labels as per Figure B.1.
Peak Label

m/z

Relative Intensity

(1)

3098.6168

3.94

(2)

3337.0012

18.17

(3)

3619.1516

12.55

4107.7135

8.53

4139.0778

8.13
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4313.2573
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4346.3899
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4380.1287

19.53
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4833.7635
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4865.8180
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(4)

(5)

(6)

(7)
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APPENDIX C – Mass Spectrometry: MS-MS GSNOR
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Figure C.1: GSNOR MS-MS Peptide Map. Highlighted amino acids are represented by
identified peptides.
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Table C.1: Full peptide list resulting from MS-MS identification. Theoretical amino
acid number corresponds to labels beginning at Met1, whereas experimental amino acid
numbers include the His tags of the recombinant protein. 292 total amino acids have been
sequenced, however only 188 unique amino acids have coverage, resulting in a 52%
sequence coverage of the 374 relevant residues. 48% coverage with His tags included.

m/z

Theoretical
Amino Acid
Number

Experimental
Amino Acid
Number

Amino Acid Sequence

813.3543
690.0621
621.4647
545.9043
406.9651
457.5103
508.7969
462.4796
762.2355
749.1952
1260.826
1017.545
889.3751
863.8682
796.6921
903.3278
646.5185
1091.721
1074.582
537.7998
950.457
1053.654
669.6493
726.2026
818.1564
1061.054
1038.94
1173.876
587.3912
1241.154
965.4494
1231.957

0-6
7-11
11-22
25-43
35-41
35-42
42-56
52-56
64-79
66-81
75-87
78-87
91-98
131-138
139-145
187-195
190-203
194-205
210-220
211-221
223-230
228-236
231-242
233-246
239-245
246-254
315-324
320-330
324-334
334-343
353-360
354-363

20-26
27-33
31-42
45-54
55-61
55-62
62-76
72-76
84-99
86-101
95-107
98-107
111-118
151-158
159-165
207-215
210-223
214-225
230-240
231-241
243-250
248-256
251-262
253-265
259-265
266-274
335-344
340-350
344-354
354-363
373-380
374-383

(S)HMANEVI(K)
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Figure D.1: GSNOR MS fingerprint, with pepsin fragmentation.
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APPENDIX D – Mass Spectrometry: HDX-MS GSNOR

Figure D.2: GSNOR HDX-MS with two seconds reaction time.
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Figure D.3: GSNOR HDX-MS with four seconds reaction time.
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Figure D.4: GSNOR + 20x GSNO MS fingerprint, with pepsin fragmentation.
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Figure D.5: GSNOR + 20x GSNO HDX-MS with two seconds reaction time.
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Figure D.6: GSNOR + 20x GSNO HDX-MS with four seconds reaction time.
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Table D.1: Representative peptide to visualize deuterium uptake.
Peak information: 889.6 m/z, and the amino acid sequence is (I)PLYIPQCG(E) of residues 91-98.
Deuterium uptake (D) and change of deuterium uptake (ΔD) is displayed.
GSNOR HDX-MS:
16ul/min acid, 2ul/min GSNOR
No
2017_10_19 (1) 31 (2.609) Cm (2:52)
889.6196
8.12e3
Deuterium
100
Exchange

GSNOR + GSNO HDX-MS:
16ul/min acid, 2ul/min GSNOR
No
2017_10_19 GSNO (1) 28 (2.359) Cm (2:59)
889.8953
5.25e3
Deuterium
100
Exchange

890.6340

%

%

890.9098

891.6270

891.9028 892.8854
893.8796

892.6313

0

Two sec
Exchange
D: 24.4%
± 2.1

m/z
890
892
894
2017_10_19 5MM (1) 2 (0.184) Cm (2:59)
890.8105
3.66e3
100

891.8035
889.7850

0

Two sec
Exchange
D: 24.0%
± 0.3

m/z
890
892
894
2017_10_19 GSNO 5MM (1) 32 (2.693) Cm (2:59)
890.9098
3.77e3
100

891.9028
889.9063

%

%

ΔD: -0.4%
892.9185

892.8192

893.9237

893.8132

0

889.8622
891.8807

0

Four sec
Exchange
D: 27.5%
± 0.5

m/z
890
892
894
2017_10_19 GSNO 10MM (1) 51 (4.282) Cm (2:59)
890.8877
2.97e3
100
891.9028

889.8843
892.9075

%

ΔD: +0.4%
%

Four sec
Exchange
D: 27.1%
± 1.6

m/z
890
892
894
2017_10_19 10MM (1) 12 (1.020) Cm (2:55)
890.8656
4.95e3
100

892.8854
893.9016
893.7580

0
890

892

0

m/z
894

890
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892

m/z
894

Table D.2: Deuterium uptake results of two second reaction time. With and without
the addition of substrate GSNO. The difference in those values is shown as a heat map,
Red = decrease in deuterium uptake, Blue = increase in uptake. The colour legend used
for crystal structure representation images is shown below.
Red
-1.8

Salmon
-0.7

Pink
-0.4

Baseline
GSNO
Δ Uptake
Deuterium Deuterium
(%) &
Uptake
Uptake
Colour
(%) (n=6) (%) (n=2)
17.2 ± 1.4 17.0 ± 0.0 -0.2 Pink
15.9 ± 2.7 15.8 ± 1.2 -0.1 Pink
12.7 ± 1.1 12.8 ± 1.2 +0.2 Sky
17.0 ± 1.2 16.7 ± 0.7 -0.3 Pink
21.3 ± 1.6 20.7 ± 0.0 -0.6 Salmon
21.6 ± 1.5 20.2 ± 0.5 -1.4 Red
11.9 ± 1.1 11.5 ± 0.5 -0.4 Pink
20.3 ± 2.1 19.2 ± 0.5 -1.2 Red
9.5 ± 0.9
9.2 ± 0.2 -0.3 Pink
9.7 ± 0.7
9.0 ± 1.0 -0.7 Salmon
18.4 ± 2.5 20.8 ± 1.2 +2.4 Blue
24.4 ± 2.1 24.0 ± 0.3 -0.4 Pink
15.7 ± 1.3 15.3 ± 0.0 -0.3 Pink
16.8 ± 1.7 17.0 ± 0.0 +0.3 Sky
25.7 ± 2.8 25.3 ± 0.0 -0.4 Pink
19.3 ± 1.6 18.3 ± 1.0 -0.9 Red
9.3 ± 0.7
9.0 ± 1.3 -0.3 Pink
16.8 ± 2.5 15.0 ± 0.0 -1.8 Red
15.1 ± 1.2 15.3 ± 0.0 +0.2 Sky
13.4 ± 1.4 12.7 ± 0.7 -0.7 Salmon
13.8 ± 0.5 15.7 ± 0.0 +1.8 Blue
19.9 ± 2.3 23.3 ± 0.0 +3.4 Blue
29.5 ± 3.5 29.7 ± 0.0 +0.1 Sky
17.1 ± 1.8 15.8 ± 1.2 -1.2 Red
15.9 ± 2.5 15.0 ± 1.0 -0.9 Red
13.7 ± 1.3 12.3 ± 0.3 -1.4 Red
14.8 ± 1.3 14.3 ± 0.3 -0.4 Pink
15.0 ± 1.1 15.3 ± 0.0 +0.3 Sky
19.3 ± 1.3 19.0 ± 0.7 -0.3 Pink
17.6 ± 1.4 18.2 ± 0.2 +0.6 Sky

Sky Blue
0

Blue
0.6

3.4

Amino
Acid Amino Acid Sequence
Residue
0-6
7-11
11-22
25-34
35-41
35-42
42-56
52-56
64-79
66-81
78-87
91-98
131-138
139-145
187-195
190-203
194-205
210-220
223-230
228-236
231-242
233-245
239-245
246-254
315-324
320-330
324-334
334-343
353-360
354-363
131

(S)HMANEVI(K)
(I)KCKAAVA/(W)
(A)/AVAWEAGKPLSI(E)
(E)/IEVAPPKAHE/(V)
(E)/VRIKIIA/(T)
(E)/VRIKIIAT(A)
(A)/TAVCHTDAYTLSGAD(P)
(T)LSGAD(P)
(V)ILGHEGAGIVESVGEG(V)
(L)/GHEGAGIVESVGEGVT(K)
(G)EGVTKLKAGD(T)
(I)PLYIPQCG(E)
(F)/TCKGKTIL/(H)
(L)/HYMGTST(F)
(T)AKLEPGSVC(A)
(L)/EPGSVCAVFGLGGV(G)
(S)VCAVFGLGGVGL/(A)
(M)GCKVAGASRII(G)
(V)DINKDKFA/(R)
(D)KFARAKEFG(A)
(A)/RAKEFGATECIN(P)
(A)/KEFGATECINPQD(F)
(T)ECINPQD(F)
(D)FSKPIQEVL/(I)
(W)/KGTAFGGWKS(V)
(F)/GGWKSVESVPK(L)
(K)SVESVPKLVSE/(Y)
(S)EYMSKKIKVD(E)
(F)/DEINKAFE/(L)
(D)EINKAFELMH(S)

Table D.3: Deuterium uptake results of four second reaction time. With and without
the addition of substrate GSNO. The difference in those values is shown as a heat map,
Red = decrease in deuterium uptake, Blue = increase in uptake. The colour legend used
for crystal structure representation images is shown below.
Red
-5.2

Salmon
-0.8

Sky Blue
0

Baseline
GSNO
Δ Uptake
Deuterium Deuterium
(%) &
Uptake
Uptake
Colour
(%) (n=6) (%) (n=2)
16.6 ± 1.8 18.7 ± 0.0 +2.1 Blue
16.4 ± 3.1 17.7 ± 0.7 +1.3 Dodger
12.3 ± 1.9 13.2 ± 0.2 +0.8 Dodger
16.5 ± 2.3 17.7 ± 0.0 +1.2 Dodger
20.3 ± 3.1 21.7 ± 0.0 +1.4 Dodger
20.4 ± 2.4 21.2 ± 0.5 +0.8 Dodger
11.7 ± 2.0 12.2 ± 0.2 +0.5 Sky
20.9 ± 2.5 21.5 ± 0.5 +0.6 Sky
9.3 ± 1.3 10.0 ± 0.0 +0.7 Sky
9.2 ± 1.4
9.5 ± 0.5 +0.3 Sky
19.2 ± 3.7 23.5 ± 3.5 +4.3 Blue
27.1 ± 1.6 27.5 ± 0.5 +0.4 Sky
15.3 ± 2.3 16.0 ± 0.0 +0.7 Sky
17.3 ± 2.7 17.7 ± 0.0 +0.3 Sky
24.9 ± 2.7 24.3 ± 0.0 -0.6 Salmon
19.3 ± 2.4 18.5 ± 1.8 -0.8 Salmon
8.8 ± 1.2
9.7 ± 0.7 +0.9 Dodger
17.7 ± 2.3 13.7 ± 0.0 -4.0 Red
14.3 ± 2.4 16.3 ± 0.3 +2.1 Blue
13.1 ± 2.4 13.2 ± 0.2 +0.1 Sky
11.0 ± 0.3 14.7 ± 0.0 +3.7 Blue
18.6 ± 4.0 23.7 ± 0.0 +5.1 Blue
30.1 ± 2.9 30.7 ± 0.0 +0.6 Sky
17.4 ± 2.3 12.2 ± 3.8 -5.2 Red
15.8 ± 3.6 15.8 ± 0.2 +0.1 Sky
13.0 ± 2.0 13.5 ± 0.2 +0.5 Sky
14.5 ± 1.6 15.3 ± 0.3 +0.8 Dodger
15.7 ± 2.2 15.3 ± 0.0 -0.3 Salmon
17.5 ± 2.8 19.7 ± 0.3 +2.2 Blue
17.2 ± 2.8 18.2 ± 0.5 +1.0 Dodger

Dodger Blue
0.7
1.4

Blue
5.1

Amino
Acid Amino Acid Sequence
Residue
0-6
7-11
11-22
25-34
35-41
35-42
42-56
52-56
64-79
66-81
78-87
91-98
131-138
139-145
187-195
190-203
194-205
210-220
223-230
228-236
231-242
233-245
239-245
246-254
315-324
320-330
324-334
334-343
353-360
354-363
132

(S)HMANEVI(K)
(I)KCKAAVA/(W)
(A)/AVAWEAGKPLSI(E)
(E)/IEVAPPKAHE/(V)
(E)/VRIKIIA/(T)
(E)/VRIKIIAT(A)
(A)/TAVCHTDAYTLSGAD(P)
(T)LSGAD(P)
(V)ILGHEGAGIVESVGEG(V)
(L)/GHEGAGIVESVGEGVT(K)
(G)EGVTKLKAGD(T)
(I)PLYIPQCG(E)
(F)/TCKGKTIL/(H)
(L)/HYMGTST(F)
(T)AKLEPGSVC(A)
(L)/EPGSVCAVFGLGGV(G)
(S)VCAVFGLGGVGL/(A)
(M)GCKVAGASRII(G)
(V)DINKDKFA/(R)
(D)KFARAKEFG(A)
(A)/RAKEFGATECIN(P)
(A)/KEFGATECINPQD(F)
(T)ECINPQD(F)
(D)FSKPIQEVL/(I)
(W)/KGTAFGGWKS(V)
(F)/GGWKSVESVPK(L)
(K)SVESVPKLVSE/(Y)
(S)EYMSKKIKVD(E)
(F)/DEINKAFE/(L)
(D)EINKAFELMH(S)
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